


Accepted Manuscript

Title: Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Authors: Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D'Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzzello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci



PII: S1590-8658(17)30145-7
DOI: <http://dx.doi.org/doi:10.1016/j.dld.2017.01.141>
Reference: YDL D 3344

To appear in: *Digestive and Liver Disease*

Received date: 9-10-2016
Accepted date: 7-1-2017

Please cite this article as: Biancone Livia, Annese Vito, Ardizzone Sandro, Armuzzi Alessandro, Calabrese Emma, Caprioli Flavio, Castiglione Fabiana, Comberlato Michele, Cottone Mario, Danese Silvio, Daperno Marco, D'Incà Renata, Frieri Giuseppe, Fries Walter, Gionchetti Paolo, Kohn Anna, Latella Giovanni, Milla Monica, Orlando Ambrogio, Papi Claudio, Petruzzello Carmelina, Riegler Gabriele, Rizzello Fernando, Saibeni Simone, Scribano Maria Lia, Vecchi Maurizio, Vernia Piero, Meucci Gianmichele. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease* <http://dx.doi.org/10.1016/j.dld.2017.01.141>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Livia Biancone^{1*}, M.D., Ph.D., Vito Annese³, M.D., Sandro Ardizzone⁴, M.D., Alessandro Armuzzi⁵, M.D., Emma Calabrese¹, M.D., Ph.D., Flavio Caprioli⁶, M.D., Ph.D., Fabiana Castiglione⁷, M.D., Michele Comberlato⁸, M.D., Mario Cottone⁹, M.D., Silvio Danese¹⁰, M.D., Marco Daperno¹¹, M.D., Renata D'Incà¹², M.D., Giuseppe Frieri¹³, M.D., Walter Fries¹⁴, M.D., Paolo Gionchetti¹⁵, M.D., Anna Kohn¹⁶, M.D., Giovanni Latella¹³, M.D., Monica Milla³, M.D., Ambrogio Orlando⁹, M.D., Claudio Papi¹⁷, M.D., Carmelina Petruzzello¹, M.D., Gabriele Riegler¹⁸, M.D., Fernando Rizzello¹⁵, M.D., Simone Saibeni¹⁹, M.D., Ph.D., Maria Lia Scribano¹⁶, M.D., Maurizio Vecchi²⁰, M.D., Piero Vernia²¹, M.D., Gianmichele Meucci^{2*}, M.D.

¹ University "Tor Vergata", Department of Systems Medicine, Rome; ² San Giuseppe Hospital, Gastroenterology, Milan; ³ AOU Careggi, Gastroenterology, Florence; ⁴ ASST Fatebenefratelli Sacco - University of Milan, Milan; ⁵ IBD Unit Complesso Integrato Columbus – Gemelli Hospital Catholic University Foundation, Rome; ⁶ Department of Pathophysiology and Transplantation, University of Milan and Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Policlinico di Milano; ⁷ Gastroenterology Unit, University 'Federico II', Naples; ⁸ Ospedale Centrale, Servizio di Endoscopia e Fisiopatologia Digestiva, Bolzano; ⁹ Az. Osp. Ospedali Riuniti Villa Sofia-Cervello, Palermo; ¹⁰ Humanitas Research Hospital and University, GI and IBD Center, Rozzano; ¹¹ A.O. Ordine Mauriziano di Torino, Turin; ¹² Department of Surgical, Oncological and Gastroenterological Sciences,

University of Padua, Italy; ¹³ University L'Aquila, Gastroenterology, L'Aquila; ¹⁴ University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina; ¹⁵ University Sant'Orsola-Malpighi, Bologna; ¹⁶ San Camillo-Forlanini Hospital, Gastroenterology, Rome; ¹⁷ IBD Unit, San Filippo Neri Hospital, Rome; ¹⁸ GI Unit, SUN, II University of Naples, Naples; ¹⁹ Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho; ²⁰ IRCCS Policlinico San Donato and University of Milan, San Donato Milanese – Milan; ²¹ Sapienza, University of Rome, all in Italy.

Address for correspondence

Livia Biancone, M.D., Ph.D.

Department of Systems Medicine, GI Unit

University "Tor Vergata" of Rome

Via Montpellier 1, 00133 Rome, Italy

Tel. +39-06-20903737; +39-06-20900969

E-mail: biancone@med.uniroma2.it

* LB and GM gave equal contribution

Abstract

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding THEIR pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNF α antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.

KEY WORDS: Inflammatory Bowel Disease, Guidelines, Safety, Medical treatments

1. Introduction

Several treatments are currently available for treating inflammatory bowel disease (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC). These treatments are primarily aminosalicylates (1-9), systemic corticosteroids (1-7), topical corticosteroids (budesonide; beclomethasone dipropionate, BDP) (10-12), and antibiotics (ciprofloxacin, metronidazole, rifaximin) (13-15). Immunomodulators, including thiopurines (azathioprine, 6-mercaptopurine, 6-MP) (1,16-20), methotrexate (21) and cyclosporine A (CsA) (22,23), also show efficacy in IBD (1,16-23). Since 1995 (24), a marked efficacy has also been shown for biologic therapies, including monoclonal antibodies against tumor necrosis factor- α (anti-TNF α) (infliximab, adalimumab, golimumab, infliximab biosimilars) (25-33) and, more recently, against integrins (vedolizumab, natalizumab) (1,2,34). Combinations of these therapies are often used.

The European Crohn's and Colitis Organization (ECCO) has published guidelines for the management of IBD (6,7). Nevertheless, national guidelines are also valuable because they take into consideration the local availability, feasibility and costs of both treatments and diagnostic approaches. National guidelines are also helpful because economic and legal issues differ between countries (35). The Italian Society of Gastroenterology and the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) have already established Italian guidelines on the use of biologics in IBD (36). However, guidelines on the safety of treatments for adult IBD patients are not yet available in Italy.

The IG-IBD therefore decided to prepare the present guidelines on the safety of IBD treatments available in Italy. The safety of the following treatments was considered: aminosalicylates, sulfasalazine, systemic and locally released

corticosteroids, ciprofloxacin, metronidazole, rifaximin, thiopurines, methotrexate, CsA, TNF α antagonists, and vedolizumab.

For this purpose, 50 gastroenterologists, all belonging to IG-IBD and working at one of 28 IBD units at Italian universities and hospitals, agreed to participate in writing these national guidelines. The working group included two coordinators (from two institutes), 26 writers (from 20 institutes), and 22 discussants (from 20 institutes). Additionally, one expert in infectious diseases, one oncologist and one general practitioner were involved in drawing up the consensus and in making the online evaluations, for a multidisciplinary approach. Overall, 53 panelists discussed and approved the text and the statements. Statements elaboration was followed by consensus conferences in order to discuss the preliminary statements. Agreement (>85%) was reached after 5 online votes. Each STATEMENT was discussed by the 53 panelists, who met in Rimini (Italy) on November 11th, 2014, for a general consensus meeting (PARTICIPANTS 43/53 panelists). Statements were further discussed and voted during 5 online voting procedures,. Dates of these 5 sequential online voting procedures were: October 5th-30th, 2014 (PARTICIPANTS 49/53 panelists); November 26th-December 12th, 2014 (PARTICIPANTS: 52/53); April 12th-29th, 2015 (PARTICIPANTS: 52/53); July 11th-28th, 2015 (PARTICIPANTS: 51/53), September 11th-October 17th, 2015 (PARTICIPANTS: 52/53). In order to formulate recommendations, each expert performed a literature search using the following key words: CD, UC, IBD, safety, treatments, aminosalicylates, sulfasalazine, systemic and low bioavailability corticosteroids, ciprofloxacin, metronidazole, rifaximin, thiopurines, azathioprine, 6-MP, methotrexate, CsA, TNF α -antagonists, infliximab, adalimumab, golimumab, infliximab-biosimilars, vedolizumab. For THE literature SEARCHES, PubMed, Embase and the Cochrane database were used, including

articles published until September 2016. The Oxford methodology was used to establish levels of evidence (Table 1) (37).

2. Aminosalicylates

Sulfasalazine (38) has been the mainstay of UC therapy for a long time. However, the frequent occurrence of adverse events (AEs) limited its use. In the 1970s, it was discovered that sulfasalazine is broken down in the ileocolonic tract to 5-aminosalicylic acid (5-ASA), the therapeutic moiety, and sulfapyridine, which serves as carrier (39). As the AEs appeared to be related to sulfapyridine, new ways to deliver 5-ASA were developed and, currently, oral mesalazine is available in several formulations with different mechanisms of release; all show a very low systemic absorption.

Two systematic reviews that compared different 5-ASA preparations (olsalazine, mesalazine, balsalazide) to placebo reported a comparable incidence of AEs leading or not to withdrawal (40,41). The proportions of treated patients experiencing ≥ 1 AE and withdrawing due to AEs were higher among those using sulfasalazine than 5-ASA (29% vs. 15% and 13% vs. 5% respectively). Olsalazine caused dose-dependent secretory diarrhea more frequently than mesalazine and balsalazide did (10% vs. 2% and 5%, respectively) (40). Other frequent AEs caused by olsalazine, mesalazine and balsalazide are nausea/vomiting (3%-8%), headache (4%-5%), abdominal pain/dyspepsia (4%-6%), rash (2%-4%), fever (3%-4%), fatigue/weakness (2%-4%), and arthralgia/myalgia (1%-3%) (40). Mesalazine also causes hepatic biochemical abnormalities in 2% of cases and pruritus in 1%.

A comparison between various 5-ASA formulations (balsalazide, pentasa, olsalazine, 5-ASA micropellets) and comparator 5-ASA formulations showed the same incidence of AEs (46% and 46%, respectively) (40). A review of all data from a

Cochrane analysis confirmed this equivalence (42). Kamm et al. (43) reported no difference between mesalazine multimatrix system (MMX), conventional 5-ASA formulations and placebo in terms of AEs, with no dose-related effects.

Side effects

Not all AEs can be classified as either dose-dependent or idiosyncratic; some may be associated with both mechanisms. In 1995, alopecia was reported as a dose-dependent side effect of 5-ASA in 1%-2% of patients (44). Idiosyncratic reactions using 5-ASA include skin rashes, fever, agranulocytosis, focal hepatitis, polyarteritis, and neurotoxicity (45-50). Data regarding pancreatitis and 5-ASA are conflicting (51-54), as there have been reports of both no increased risk (55) and a 4- to 9-fold increased risk (56,57). Many of the AEs associated with sulfasalazine have been ascribed to sulfapyridine (45,53,58,59). This observation is supported by the correlations between AEs and both serum sulfapyridine levels and slow sulfadimidine acetylator phenotype (60). Initially, hematological side effects were ascribed to the sulfapyridine moiety of sulfasalazine. However, these AEs have also been observed with mesalazine, with reports of thrombocytopenia (61,62), leukopenia (62-64) and aplastic anemia (65,66). In most of these cases, the AEs are both idiosyncratic and dose-independent (67).

Mesalazine-induced pericarditis has low incidence and mostly occurs during the first weeks of treatment (68). This AE is considered an acute hypersensitivity reaction against 5-ASA (68-70). Overall, long-term 5-ASA treatment is widely considered safe. Severe AEs are rare (6,7,71,72).

Renal toxicity

The most controversial mesalazine-related AE is probably renal toxicity (73,74). Elevated urinary levels of markers of renal tubular damage were found in

20%-30% of IBD patients (75). The damaged renal function is believed to be an extraintestinal manifestation of IBD or the result of an inflammatory process (75,76). Thus, also IBD patients not using 5-ASA may be at risk of renal disease. European and American guidelines therefore recommend regular renal function monitoring (77,78).

Several cases of 5-ASA-induced interstitial nephritis have been reported (79-83). Because this complication presents with nonspecific symptoms and signs, detection may be delayed for months. The incidence of 5-ASA-related nephrotoxicity is <0.5% (79,83). About 50% of cases of 5-ASA-induced interstitial nephritis develop in less than 1 year (80). Therefore, serum creatinine monitoring is recommended at 3- to 6-month intervals during the first year and annually thereafter (7,77). There is no evidence that more frequent testing improves patient outcome. Mesalazine should be withdrawn when renal impairment occurs. If renal function does not improve, renal biopsy should be considered (83).

Pregnancy

The classification of each treatment used in IBD, according to the pregnancy categories of the US Food and Drug Administration (FDA), is given in Table 2 [84]. Mesalazine, sulfasalazine and balsalazide are category B drugs for pregnancy, whereas olsalazine is included in category C. Mesalazine use has not been associated with an increased risk of complicated pregnancy in IBD patients. However, there have been reports of mesalazine-related preterm deliveries and low birth weight (85-93). Continuing mesalazine throughout pregnancy is strongly recommended, since IBD reactivation during pregnancy is more harmful than treatment (94).

Surgery

No studies have specifically addressed the safety of mesalazine in patients undergoing surgery. There is no evidence that mesalazine is associated with surgical complications.

Statement 1

The safety of 5-ASA formulations, for both oral and rectal use, is established at all approved doses [EL1]. Sulfasalazine may cause some AEs due to the systemic absorption of sulfapyridine [EL5].

Statement 2

Renal function should be monitored at least yearly during treatment [EL3]. In patients with chronic renal failure, renal function should be monitored more closely [EL3].

Statement 3

Mesalazine appears to be safe during pregnancy [EL1] and lactation [EL5]. In case of treatment with salazopyrin, folate supplementation is recommended [EL5].

3. Systemic corticosteroids

Systematically acting corticosteroids significantly reduce mortality related to IBD activity, as almost 80% of patients with active disease have a positive treatment

response (6,7). Nonetheless, these drugs cause several side effects that limit their recurrent or long-term use.

Hemorrhagic risk

The risk of peptic ulcer and gastroduodenal bleeding is irrelevant. Proton pump inhibitors are therefore not needed when using corticosteroids. This point has been made by the Italian drug agency (Agenzia Italiana del Farmaco, AIFA) (95).

Diabetes, hypertension and metabolic disorders

Corticosteroids can increase blood glucose and compromise glycometabolic balance in non-diabetic individuals. Long-term use (6-18 months) of these drugs can therefore cause weight gain, cushingoid habitus and reduced muscle mass (96-98). Arterial hypertension is thought to develop in 20% of patients using corticosteroids (96,97). Long-term corticosteroid use also modifies hypophysis–adrenal gland feedback, and may therefore reduce endogenous synthesis of glucocorticoids (6,7). An abrupt discontinuation of corticosteroids may cause temporary adrenal failure (6,7). Therefore, tapering is recommended in order to avoid adrenal failure (6,7,99). Other symptoms include fatigue, malaise, fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful and itching dermal lumps, and weight gain.

Surgical complications

Corticosteroids mainly induce infections related to *Candida* spp. (6,7,100). No specific infection appears to be associated with immunomodulators (101). When taken before surgery, corticosteroids (particularly at higher doses) increase the risk of infectious and non-infectious complications in patients with IBD (102-104).

Osteopenia and osteoporosis

Increased risks of bone mass reduction and bone fracture in corticosteroid-treated patients have been shown in a meta-analysis (105). These risks were

significant for patients TAKING corticosteroids >5 mg/day for 3-6 months, and decreased after withdrawal. Chronic corticosteroid use increases the risk of osteoporotic fractures independently of bone mineral density (106). In children, corticosteroids inhibit linear growth, delay skeletal maturation, and reduce final height and bone mineralization (6,7). Osteonecrosis of the femoral head is an uncommon albeit worrisome complication (107).

Pregnancy, breastfeeding, fertility

Corticosteroids do not interfere with pregnancy, breastfeeding or fertility in females. Sperm quality is not altered by steroids (108,109). The FDA classifies systemic corticosteroids in pregnancy category C (Table 2).

Ocular manifestations

The most frequent corticosteroid-induced ocular AEs are posterior subcapsular cataract and glaucoma (110). Corticosteroid-induced cataract cannot be prevented (6,7,111). In patients with uncontrolled glaucoma, corticosteroids must be withdrawn; intra-ocular pressure will normalize within 2-4 weeks (6,7,111). The frequency of these AEs ranges from 10% to 15%, depending on dosage, duration and individual predisposition (6,7,111).

Psychological and behavioral disturbances

Psychiatric disorders (affective, behavioral, cognitive) are not observed in IBD patients taking low corticosteroid doses (<20 mg/day), while these AEs may occur in those taking higher doses (1.3% at 40 mg/day; 5% at 41-80 mg/day) (98).

Mortality

In a multivariate logistic regression analysis of the TREAT registry, an increased mortality risk in CD (OR 2.10) was associated with the use of prednisone (112).

Statement 4

In short-term therapy, steroid side effects are usually limited [EL3]. Treatment with proton pump inhibitors is generally not recommended [EL1].

Statement 5

The most frequent side effects associated with prolonged use of steroids are hypertension, diabetes, osteopenia, osteoporosis, cataract and glaucoma [EL1]. Patients should be checked regularly for blood and ocular pressures, plasma glucose levels, glucose tolerance, and bone mineral density [EL5]. The use of steroids for more than 3 months should be avoided [EL3].

Statement 6

Elective surgery should be avoided in persons taking prednisone ≥ 20 mg/day (or equivalent) in order to avoid post-surgical complications [EL3].

Statement 7

The short-term use of steroids does not influence fertility or pregnancy; their use during pregnancy is safe [EL1].

4. Low bioavailability corticosteroids

Budesonide and beclomethasone dipropionate (BDP) have high topical glucocorticoid activity. After mucosal absorption, these drugs enter the bloodstream and are inactivated by the liver, with limited residual systemic glucocorticoid activity. However, because only 80%-90% of circulating molecules are inactivated, these drugs can cause some AEs (113).

Budesonide (9 mg/day) is an established treatment for mild-moderate ileocecal CD (12). BDP (5-10 mg/day) (11) and, more recently, budesonide coated in MMx system, showed efficacy in mild-moderate UC (114).

Short-term side effects

Several randomized controlled trials (RCTs) compared budesonide with placebo (115,116), 5-ASA (117,118) or systemic corticosteroids (119-123) in patients with active CD. In active UC, budesonide has been compared with placebo (114,124,125), 5-ASA (124,126) and systemic corticosteroids (127).

In one double-blind RCT, the rates of AEs and corticosteroid-related side effects were similar between budesonide, placebo and 5-ASA, with the exception of moon face (115). This favorable safety profile was also observed for budesonide MMx (128). When compared with systemic corticosteroids, budesonide induced a similar rate of total AEs, but a lower rate of corticosteroids-related AEs (129). In the few RCTs that compared BDP with placebo, AEs were infrequent and generally not serious (12,130,131). When BDP was compared with systemic corticosteroids, the rate of AEs was comparable (122,131).

Long-term side effects

Budesonide has been compared with placebo, in patients with CD, for maintaining remission in CD (11,132-136) and for preventing post-operative recurrence of CD (137-138). In these studies, the rates of side effects were comparable between the two treatment groups, with the exception of moon face (133) and bruising (135). Budesonide caused fewer corticosteroid-related AEs than prednisolone (139). Other AEs from budesonide are acne, moon face, hirsutism, mood swings, insomnia, weight gain, striae, and hair loss. A double-blind, placebo-

controlled RCT reported comparable frequencies of AEs in CD patients treated with BDP (51.4%) or with placebo (58.3%) (140).

Adrenal suppression/withdrawal symptoms

Low bioavailability corticosteroids are more likely to cause a significant reduction in plasma cortisol levels than 5-ASA or placebo (113-116,122,123,130-132, 136). Budesonide (119,121) and BDP (131) induce a comparable reduction in plasma cortisol levels, which nonetheless is less clinically relevant than the reduction induced by systemic corticosteroids. Impaired adrenal function (seen as altered results on adrenocorticoid stimulation tests) develops in a higher proportion of IBD patients using budesonide than 5-ASA or placebo (in both the short and long terms, even at a low dose such as 3 mg/day) (135,139).

Bone damage

Short-term budesonide use does not appear to impair osteoblast activity in CD (141). In a randomized 2-year study (138), bone mineral density was better preserved in patients taking budesonide than prednisone in mild-moderate corticosteroid-naïve CD, but not in patients with steroid dependence or previous exposure to corticosteroids. In a 2-year prospective study (142), budesonide was associated with bone loss, without advantage over low-dose prednisone.

Other side effects

In a pooled safety analysis of five double-blind, placebo-controlled RCTs at 1 year (143), cutaneous glucocorticoid signs were more frequent in patients who were using budesonide ($p=0.0036$). Clinically relevant AEs were rare and similar between groups.

Surgery

Budesonide and BDP are both considered pregnancy category C drugs (Table 2). Systemic corticosteroids have been suggested for patients using budesonide or BDP requiring emergency surgery (115). The risk of surgical complications in IBD patients treated with budesonide or BDP is undefined.

Pregnancy and breastfeeding

A few studies have reported the safety of oral budesonide and BDP in pregnancy or breastfeeding. No maternal or fetal AEs were reported for eight pregnant women taking budesonide (6-9 mg/day) for IBD (144). In asthmatic pregnant women, use of inhaled budesonide was not associated with an increased risk of congenital malformations, cardiovascular defects, decreased gestational age, or reduced birth weight/length (145). According to a systematic review, only one of nine included studies of BDP for asthma in pregnant women without IBD reported an increased risk of congenital abnormalities (146). No similar data are available regarding patients with IBD. Although budesonide and BDP are secreted in breast milk, the levels of these drugs in breast milk and in lactating infants' plasma are low (147,148). Therefore, these drugs are considered compatible with breastfeeding (147,148). However, we suggest that the decision to prescribe low-bioavailability corticosteroids to nursing women be made on a case-by-case basis.

Statement 8

In the short term, BDP and budesonide appear to be safer than systemic steroids [EL1].

Statement 9

In the long term, budesonide treatment leads to adrenal suppression, has a negative effect on bone mineral density, and may cause cutaneous glucocorticoid

signs [EL1]. Moreover, considering its lack of effectiveness in maintenance therapy, its use should not last for more than 3 months following induction of remission [EL5].

Statement 10

The use of budesonide and BDP during lactation should be evaluated case by case [EL5].

5. Antibiotics

In IBD, antibiotics are appropriate for treating perianal CD, septic complications, bacterial overgrowth, and active pouchitis (6,7,149,150). The main antibiotics used in IBD are ciprofloxacin, metronidazole and rifaximin.

Ciprofloxacin

Ciprofloxacin is safe and well tolerated (151). Most AEs due to ciprofloxacin are mild and self-limiting, and rarely require the drug's discontinuation. Gastrointestinal toxicity (nausea, dyspepsia, vomiting, abdominal pain, constipation, diarrhea) occurs in $\leq 20\%$ of patients (151,152). Ciprofloxacin may cause *C. difficile* infection, inducing IBD relapse (153). Mild, transient elevations of TRANSAMINASES and alkaline phosphatase are occasionally observed (154). Rarely, serious acute liver injury, mainly related to idiosyncratic hypersensitivity, has been reported (154). Pre-existing liver disease is a risk factor for a poorer outcome (154). Hypo- or hyperglycemia may be observed (152).

During ciprofloxacin treatment, patients may experience neurological and psychiatric events such as headache, insomnia, somnolence, CONFUSION state,

acute psychosis, delirium, convulsions and dizziness (152,155). Ciprofloxacin should be used with caution in patients with a history of seizures.

Ciprofloxacin can cause arthropathy, primarily in weight-bearing joints and especially in pediatric patients (156,157). Tendinitis and tendon rupture, primarily affecting the Achilles tendon, may occur. This event is rare, with an excess risk of 3.2 cases/1000 patient-years (158). Corticosteroid use, old age and intense physical activity enhance this risk (159). As QT interval prolongation has been observed in quinolone treatment (160), ciprofloxacin should be avoided in patients with this abnormality or other risk factors for tachyarrhythmia. Finally, a common complication of ciprofloxacin use is mild-to-severe phototoxicity (151,152).

Metronidazole

The incidence of AEs in patients using metronidazole varies according to the dose and duration. Long-term use (3 months) at high dose (20 mg/kg day) induced AEs in 38% of patients (161). AEs from metronidazole include metallic taste, nausea, anorexia and diarrhea. Hypersensitivity reactions (e.g. fever, rash, itch, flush, vomiting, abdominal cramp, headache, stomatitis, glossitis, dry mouth) may occur. These symptoms usually resolve with dose reduction or cessation. Rarely, a disulfiram-like reaction after alcohol consumption may develop, although the role of this interaction is debated (162). Dark-colored urine and transient reversible neutropenia may occur in patients taking high-dose metronidazole (163). It is useful to closely monitor leukocyte levels, in patients assuming METRONIDAZOLE combined with immunosuppressives.

AEs from metronidazole involving the central nervous system include dizziness, encephalopathy, seizure, cerebellar ataxia and, more frequently, peripheral neuropathy (164) leading to paresthesias or subclinical delayed nerve

conduction. These neurological AEs occur in up to 85% of patients after long-term treatment with high doses (20 mg/kg day) (161,165,166). These symptoms and structural lesions usually resolve after drug withdrawal, although the peripheral neuropathy may take several months to resolve; if treatment is continued, the symptoms may become irreversible.

Rifaximin

Rifaximin has an excellent safety profile, with AEs occurring in $\leq 2\%$ of patients (167,168). Common AEs are flatulence, abdominal pain, nausea and vomiting. Increased serum potassium and sodium levels, although within the normal range, may occur. Long-term treatment with high doses of rifaximin has been associated with urticarial skin reactions (167,168).

Use of antibiotics by pregnant or lactating women

Two studies of pregnant women taking ciprofloxacin did not observe any risk of spontaneous abortion or congenital malformation associated with this drug (169,170). Overall, ciprofloxacin is thought to present minimal risk to pregnant women. However, the ECCO guidelines (171) suggest avoiding ciprofloxacin during the first trimester, while for the FDA ciprofloxacin is included in pregnancy category C (172). Because ciprofloxacin is excreted in breast milk, ECCO recommends that it not be taken by lactating women (171).

Metronidazole use in pregnant women has been associated with an increased risk of infant cleft lip, with or without cleft palate (173,176), although two meta-analyses found no relationship between metronidazole exposure during pregnancy and birth defects (174,175). Metronidazole is considered a low-risk drug for pregnant women (FDA pregnancy category B). However, its use during the first trimester is not

recommended (171,172). Metronidazole IS SECRETED IN breast milk (177) and, therefore, breastfeeding should be avoided during treatment.

Finally there are no relevant data regarding teratogenicity of rifaximin in humans (FDA category C) (172). The American Gastroenterological Association suggests that rifaximin is probably compatible with breastfeeding, but data are lacking (172).

Statement 11

Gastrointestinal intolerance is the most common side effect of ciprofloxacin, observed in up to 20% of patients [EL2]. Ciprofloxacin can cause Clostridium difficile infection [EL4]. Concomitant use of steroids and ciprofloxacin, especially in the elderly, should be avoided due to the risk of tendinitis and tendon rupture [EL4].

Statement 12

Usual side effects of metronidazole include metallic taste, nausea, anorexia and diarrhea, which usually resolve with dose reduction or drug discontinuation [EL2]. Peripheral neuropathy is reported in up to 85% of patients treated at high doses (20 mg/kg day) for long time [EL3]. Neuropathy may be irreversible if treatment continues [EL4].

Statement 13

Side effects of rifaximin are reported in less than 2% of patients, and mostly concern the gastrointestinal tract [EL3].

Statement 14

Ciprofloxacin and metronidazole should be avoided during pregnancy, especially in the first trimester [EL5]. However, short-term courses of metronidazole are possible during the second and third trimesters [EL5]. Rifaximin should be avoided during pregnancy [EL5]. Ciprofloxacin and metronidazole should be avoided during lactation [EL5], while rifaximin is probably safe [EL5].

6. Thiopurines

Thiopurines, including 6-mercaptopurine and its prodrug azathioprine, induce AEs in more than 30% of IBD patients. Drug discontinuation is required in 20%-40% of these cases (178-181). The estimated number needed to harm (NNH) is 14 (182). Thiopurine AEs may be dose-unrelated (idiosyncratic or allergic, probably immune-mediated) or dose-related.

Idiosyncratic AEs generally occur early. The most common forms of these AEs are nausea, vomiting, pancreatitis, cutaneous eruption and hepatitis, most often associated with systemic symptoms (e.g. malaise, fever, and articular or muscular pain). Pancreatitis is usually mild; it occurs in 1%-4% of patients, mainly females, within 1 month, although a later onset is possible (178-181). Rechallenge with any thiopurine almost invariably leads to recurrent pancreatitis. Cutaneous eruptions are often under-recognized because they can mimic infections or the exacerbation of an underlying cutaneous disease. The most common manifestation of hypersensitivity is neutrophilic dermatosis, which in some cases meets the criteria of drug-induced Sweet's syndrome (183).

Dose-related AEs, including myelotoxicity and liver toxicity, may occur at any time. Myelotoxicity (leading to anemia, leukopenia or thrombocytopenia) often occurs

early (≤ 8 weeks), although it may develop even after years (184). Although leukopenia, particularly lymphopenia, is considered a marker of responsiveness, an excessive suppression of leukocyte count may lead to infections. The incidence of myelotoxicity has been estimated to be approximately 3% per year of treatment (185).

The risk of myelotoxicity is influenced by the activity of the enzyme thiopurine methyl transferase (TPMT), which catalyzes the methylation of 6-mercaptopurine to 6-methylmercaptopurine (6-MMP) (186,187). Subjects with genetically determined negligible TPMT activity have diminished or absent 6-MMP levels and consequently higher rates of conversion of 6-mercaptopurine into 6-thioguanine (186-189). 6-Thioguanine levels have been associated with thiopurine efficacy, while 6-MMP levels ARE associated with drug-related toxicity (190-192). Testing for TPMT activity has therefore been suggested to predict thiopurine toxicity, including bone marrow suppression (191,193,194), although with conflicting findings (195,196). The cost-effectiveness of TPMT testing (197,198) needs to be re-evaluated (199-202).

Liver toxicity, seen as elevations in serum levels of transaminases or cholestatic enzymes, develops in up to 12% of patients (203) and is related to high levels of 6-MMP (190,191,194). Dose reduction may REVERSE this AE, and a meta-analysis suggested that shifting from azathioprine to 6-mercaptopurine is effective (204). Mercaptopurine-induced hepatoportal sclerosis, leading to portal hypertension, is occasionally observed (206). No recommendations for preventing fibrosis and portal hypertension in non-cirrhotic patients using long-term thiopurine therapy are available.

Nodular regenerative hyperplasia occasionally occurs in patients taking thiopurines. The cumulative incidence at 5 and 10 years is 0.6% and 1.28%,

respectively, but the risk of this complication is higher in patients taking higher doses. Nodular regenerative hyperplasia, however, also occurs in thiopurine-naïve IBD patients with an incidence of 6%; IBD may be an independent predisposing risk factor to this condition (207).

Risk assessment for thiopurine AEs

Full blood count, liver function tests, and screening for viral infections (HIV, HCV, HBV) should be done before prescribing thiopurines. Liver function tests and full blood count should be done frequently in the first 2 months. A single schedule for laboratory assessments during treatment is not available, as national associations provide different recommendations. A general recommendation is a tighter surveillance during the first 1-2 months, with longer intervals thereafter (full blood count every 2-3 months). Severe leukopenia (neutrophils $<1000/\text{mm}^3$) requires immediate drug discontinuation, as does mild leukopenia (WBC $<3000/\text{mm}^3$ or neutrophils $<2000/\text{mm}^3$) occurring very early during treatment. Differently, mild leukopenia occurring during long-term treatment may be managed with dose reduction and strict monitoring (178,202).

In HBsAg-positive patients, antiviral therapy is recommended. In “isolated” anti-HBc-positive patients, transaminases and HBV DNA should be assessed every 3 months (208).

Thiopurines in combination therapy

Thiopurines are frequently combined with 5-ASA in IBD. This combination has been associated with enhanced thiopurine toxicity, due to the concomitant effect of 5-ASA on erythrocyte 6-thioguanine levels (209,210). The clinical relevance of this effect is not clear, and current data do not support the need to avoid this combination.

The combination of low-dose thiopurines and allopurinol has been suggested to reduce the risk of hepatic and non-hepatic AEs. Allopurinol may inhibit the enzyme xanthine oxidase involved in the generation of 6-MMP (211,212). Current evidence, however, does not support the use of this combination.

Thiopurines and opportunistic infections

Thiopurine-treated IBD patients have a 3-fold increased risk of opportunistic infections, while IBD patients receiving thiopurines and steroids have a 5-fold increased risk (103,213,214). A broad spectrum of opportunistic infections has been reported, varying from mild to lethal. These include: viral infections with Epstein-Barr virus (EBV), cytomegalovirus, herpes simplex, varicella-zoster and parvovirus; bacterial infections with *Listeria monocytogenes* or *Mycobacterium tuberculosis*; and fungal infections with *Pneumocystis jiroveci* or *Aspergillus fumigates*. Viral infections and sepsis represent additional RISK factors for myelosuppression. The hemophagocytic lymphohistiocytic syndrome associated with a high mortality ($\leq 30\%$) may complicate these infections in patients using thiopurines (215).

Thiopurines and cancer risk

Since the 1980s, a relation between lymphoma and thiopurine use has been postulated in IBD patients, who are already at increased lymphoma risk (216-219). Although azathioprine increases the life expectancy (0.04 years) and the quality of life (220) of CD patients, this gain decreases with increasing age and the lymphoma risk. Thiopurines are associated with EBV-positive lymphoma in IBD (221). In 2003, A meta-analysis found an increased lymphoma risk in IBD patients using thiopurines, with a standardized incidence ratio of 4.18 (95% CI, 2.07–7.51) despite marked heterogeneity among studies (222). A subsequent prospective observational study confirmed, in France, the higher incidence of lymphoproliferative disorders in patients

receiving thiopurines than in those who discontinued or never received thiopurines; this risk increased with age and years of treatment (223). A single-center Dutch study also reported a significantly increased lymphoma risk in IBD, with a correlation between EBV-positive lymphoma and thiopurines (224). A rare, often fatal hepatosplenic T-cell lymphoma has been reported in patients using azathioprine, particularly when combined with TNF α antagonists (see Section 10).

An association between thiopurine use and non-melanoma skin cancer (NMSC) has been reported in CD (225-229). In some studies (225-228), the incidence of NMSC was higher in IBD patients than in controls; in one of these studies, the incidence rate ratio was 1.64 (225). However, use of thiopurines further increased this risk (OR, from 3.56 to 4.27) (226-229). A meta-analysis found, instead, that the risk of NMSC is only modestly elevated in IBD and argued that the discrepancies between population- and hospital-based studies were evidence of ascertainment bias (229).

Recently, a prospective observational study found that IBD patients receiving thiopurines had an increased risk of urinary tract cancers: the multivariate, adjusted hazards ratio between patients who received and those who did not receive thiopurines was 2.82 (95% CI, 1.04–7.68) (230). Clinically relevant excess risk was observed in older men (230).

Surgery

Thiopurine monotherapy in IBD patients undergoing elective surgery is not associated with an increased risk of complications (231,232).

Pregnancy and breastfeeding

Azathioprine and 6-mercaptopurine are category D drugs for pregnancy and lactation (Table 2). However, this classification is based on old studies concerning

high doses of thiopurines for leukemia (233). Although few data are available, clinical trials and case series suggest that thiopurines are safe in pregnancy and lactation (234-236).

An increased risk of preterm birth was reported in pregnant patients using thiopurines, together with higher risk of anemia, pancytopenia and alkaline phosphatase elevation in babies exposed to thiopurines in utero. However, evidence is conflicting (237). In clinical practice, IBD activity, rather than thiopurine use, appears to be the major risk factor for complications during pregnancy and delivery. Therefore, thiopurine withdrawal is not recommended in patients at high risk for relapse. No increased risk of congenital abnormalities has been observed in children whose fathers were TAKING thiopurines at conception (238-240).

Statement 15

Thiopurines may induce adverse events in up to 30% of patients even in the short term, requiring drug discontinuation [EL2]. Myelotoxicity, hepatitis and acute pancreatitis are the most relevant side effects [EL2]. Thiopurine use is associated with an increased risk of non-melanoma skin cancer and lymphoma [EL1].

Statement 16

Switching to 6-mercaptopurine is a possible strategy for patients with azathioprine intolerance to avoid most AEs except for acute pancreatitis or bone marrow suppression [EL4].

Statement 17

Full blood count and liver function tests as well as HIV, HCV and HBV screening are indicated before starting thiopurines [EL5].

Statement 18

In HBsAg-positive patients, antiviral therapy is recommended. In “isolated” anti-HBc-positive patients, transaminases and viremia (HBV DNA) should be assessed every 3 months, but antiviral therapy is recommended only if viremia is detected [EL5]. There is insufficient evidence on which to base a recommendation for how long to treat these patients [EL5].

Statement 19

There is insufficient evidence regarding the ideal duration of treatment with thiopurines, although prolonged treatment (>5 years) can be considered on a case-by-case basis [EL4]. In patients starting thiopurines, liver function tests and full blood count should be done frequently in the first 2 months. Thereafter, full blood count should be monitored every 2-3 months but the optimal timing for liver function testing is not established [EL5]. Dose reduction or discontinuation is indicated in cases of bone marrow or liver toxicity [EL5]. Pancreatitis requires drug discontinuation [EL1].

Statement 20

Thiopurines are contraindicated in patients with active infections or neutropenia (neutrophils $<1000 \text{ mm}^3$) [EL1]. Thiopurines should be used with caution in patients with a history of neoplasia [EL5]. Thiopurines should be used with caution in elderly patients and EBV-negative young men, due to their increased risk of lymphoma [EL2].

Statement 21

Thiopurines are generally safe during pregnancy and lactation [EL2], although an increased risk of preterm births has been observed [EL2]. Male patients should not stop therapy when planning to procreate [EL5].

7. Methotrexate

Methotrexate may induce gastrointestinal intolerance, hepatic toxicity, bone marrow suppression, and hypersensitivity pneumonitis. Nausea and vomiting occur in up to 40% of IBD patients treated with methotrexate (21,241) and may require drug discontinuation. Folic acid supplementation may reduce the incidence of gastrointestinal symptoms (242).

Hepatic fibrosis is the most significant AE of methotrexate use, and is correlated with long-term treatment. This observation COMES from a study of psoriatic patients who TOOK methotrexate daily, leading to high hepatic drug concentrations and a high frequency of liver damage, with cirrhosis or active hepatitis seen in up to 23% of cases) (243). High intrahepatic concentrations are not achieved in patients who follow a once-weekly schedule (244). This may account for the low prevalence of hepatic toxicity in RCTs and case series of IBD patients, indicating that the reversible elevation of transaminases is the most frequent AE in methotrexate-treated IBD patients (245-247). In a meta-analysis, the pooled incidence rate of abnormal aminotransferase levels (≤ 2 -fold increase) in methotrexate-treated patients was 1.4/100 person-months, while the rate of hepatotoxicity (≥ 2 -fold increase) was 0.9/100 person-months (248).

Methotrexate-induced pathological liver changes in IBD have been investigated in few studies. In one study of 11 patients treated for a median of 18 months (range 7-58) with a mean cumulative dose of 1225 mg (range 220-3400 mg), there were 5 cases of mild steatosis and one case each of granulomatous hepatitis with mild portal fibrosis, slight sinusoid dilation, and periportal fibrosis, while a normal biopsy was reported in the remaining three cases (249). In another study, 20 patients had liver biopsy after a mean methotrexate duration of 131.7 weeks (range 66-281) and a mean cumulative dose of 2633 mg (range 1500-5410 mg): biopsy was normal or showed Roenigk's grade I histological changes in 17 patients (85%) while the remaining 3 patients had grade II-IIIb changes (250). Abnormal serum transaminase levels are not predictive of hepatic histological changes (250). Alcohol consumption, obesity, diabetes mellitus, >1500 mg dose and frequent dosing intervals are risk factors for liver injury in psoriatic patients (243). Prophylactic folate supplementation may reduce hepatic AEs, although controlled studies have not been done in IBD patients. Reactivation of HBV infection has been reported in rheumatic diseases (251), but again data in IBD are lacking.

The extent of liver fibrosis in IBD patients treated with methotrexate can be assessed by "transient elastography" using a FibroScan device. However, in one series (252), FibroScan findings did not correlate with the cumulative methotrexate dose, suggesting the need to reconsider total dose as a risk factor for hepatic fibrosis in IBD.

The American College of Rheumatology recommends liver biopsy before treatment with methotrexate if chronic liver disease is suspected (253). Liver biopsy during treatment is recommended when aspartate aminotransferase (AST) levels are high THROUGHOUT the year (repeated every 4-8 weeks) and in cases of

hypoalbuminemia. Dose reduction is recommended in cases of high AST, while moderate-to-severe fibrosis or cirrhosis requires discontinuation.

Pregnancy and breastfeeding

Methotrexate is embryotoxic and absolutely contraindicated during pregnancy (FDA pregnancy category X), as it causes severe malformations including anencephaly, hydrocephaly and meningomyelocele (254). Craniofacial and limb defects are also possible. Adequate contraception must be used by women of childbearing age during treatment, and methotrexate should be stopped ≥ 3 months before planning a pregnancy. In this period, folate supplementation is strongly recommended.

The incidence of myelosuppression and hypersensitivity pneumonitis in IBD patients TAKING methotrexate has not been reported. Myelotoxicity was observed in 4.5% of patients in a multicenter retrospective study, after a median treatment duration of 17 months (255).

Statement 22

Gastrointestinal intolerance is observed in up to 40% of patients treated with methotrexate, and is reversible upon drug discontinuation [EL1]. Oral folic acid administration [EL1] and dose fractionation [EL4] can reduce the incidence of methotrexate-induced gastrointestinal intolerance.

Statement 23

A complete medical history, including daily alcohol intake and serology for HBV and HCV, must be obtained before initiating methotrexate treatment [EL5]. Routine blood testing, including complete blood count and serum transaminases, is recommended in patients treated with methotrexate, and should be done at baseline, after 4 weeks of treatment, and then every 12 weeks [EL4].

Statement 24

Methotrexate therapy is contraindicated in patients with active viral hepatitis, severe fibrosis or cirrhosis (stages F3 or F4 on the METAVIR scoring system), or chronic HBV infection [EL4]. A pretreatment liver biopsy should be performed in patients with suspected chronic liver disease [EL4].

Statement 25

Methotrexate treatment is frequently associated with a slight increase in serum transaminases (up to 2-fold above normal range) [EL1]. This change is not predictive of significant liver toxicity and fibrosis and does not warrant drug discontinuation [EL4].

Statement 26

Methotrexate should be discontinued in cases of a persistent, significant increase of serum transaminases (≥ 2 -fold above the upper limit of normal over a period of 4 weeks) [EL4]. A significant increase in serum transaminases, which persists following drug discontinuation, or the development of clinical or laboratory signs of chronic liver disease is an indication for liver biopsy [EL4].

Statement 27

Non-invasive evaluation of liver fibrosis may be a useful tool to monitor liver fibrosis in IBD patients receiving methotrexate treatment [EL3].

Statement 28

Methotrexate is embryotoxic and absolutely contraindicated in the pre-conception period for men and woman and during pregnancy [EL 1]. Adequate contraception must be used by women of childbearing age if they wish to take methotrexate. Before conception, methotrexate must be avoided for 3-6 months.

8. Cyclosporine A

Cyclosporine A (CsA) can cause dose-dependent and dose-independent AEs. Dose-dependent AEs associated with CsA use include renal toxicity, hypertension, lymphoma, infections, seizures, paresthesias hypertrichosis, and anaphylaxis. In older studies, where >5 mg/kg day CsA was administered, 329 AEs were reported in 343 patients (0.94 AE/patient) (256). This rate can be markedly reduced by monitoring the serum concentration of CsA every other day and maintaining blood levels between 100 and 450 ng/ml (22,257). A double-blind RCT that compared clinical outcomes between patients who received intravenous CsA at 2 or 4 mg/kg found a further, although not significant, reduced incidence of AEs in the 2 mg/kg group (23). The lower dose has thus been preferred.

Cholesterol levels should be assessed before therapy. CsA blood levels require regular monitoring since, after oral administration, CsA metabolism and absorption may show wide interindividual variations (256).

Opportunistic infections

High-dose CsA (>5 mg/kg day) is associated with infectious complications, including *Pneumocystis jiroveci* pneumonia, herpes esophagitis, mycotic aneurysm, and staphylococcal sepsis (256). Concomitant corticosteroids or thiopurines increase the risk. *Pneumocystis jiroveci* prophylaxis is recommended when using ≥ 1 immunosuppressive drug (calcineurin inhibitor or TNF α antagonist) (104, 258). In a retrospective UC cohort (76 patients who received either 4 mg/kg intravenously or 5 mg/kg orally), with an up to 7-year follow-up, no infections were reported and CsA was stopped in only 4 cases for noninfectious AEs (seizures, urticaria, renal failure or hypertension) (259).

Cancer risk

Malignancies are more frequent in patients with renal, heart or liver transplantation after long-term treatment with CsA than in transplant recipients who did not take CsA. The increased risk is related to CsA dose and duration, and is lower than that observed in transplant recipients using thiopurines or tacrolimus (260). Fewer malignancies were observed using lower CsA doses (<5 mg/kg day) (261). As these data refer to transplant recipients and patients with other immune-mediated diseases, these conclusions may not apply to IBD patients. An increased risk of NMSC has been documented in CsA-treated patients with psoriasis or rheumatoid arthritis (262), but not in CsA-treated IBD patients (263). In solid organ transplant recipients, CsA use leads to a 200-fold increase in skin cancer, particularly squamous cell cancer (264,265). Low-doses (75-125 ng/ml) were associated with significantly fewer malignancies (266).

Surgery

CsA does not increase the risk of peri-operative or postoperative complications in adult UC patients (25,267,268).

Reproductive health

CsA and modified CsA (Neoral) did not have significant effects on female or male fertility in transplant series (269,270). CsA is a FDA pregnancy category C drug (Table 2). This treatment does not increase the risk of congenital malformation, but it does slightly, but not significantly increase the risk of premature delivery and low birth weight (271,272). It is unclear whether these findings are related to CsA or the underlying disease. Case reports and small series support the safety of CsA in pregnant patients with severe IBD (273). CsA may therefore be used as rescue therapy during pregnancy in severe, refractory IBD.

CsA is excreted at a small rate into breast milk (172). The American Gastroenterological Association considers CsA use during lactation to be safe (172). Nonetheless, breastfeeding by women taking CsA is discouraged due to the potential induction of immunosuppression in the newborn.

Statement 29

In the case of idiosyncratic AE, a switch from parenteral to oral CsA appears to be safe [EL4].

Statement 30

Regular monitoring of serum levels of CsA is recommended [EL2]. Cholesterol should be checked before the institution of therapy. Fasting blood glucose, electrolytes (including magnesium), renal function and blood pressure should be monitored every 2 days and fortnightly for intravenous and oral administration, respectively [EL3].

Statement 31

*The use of 2 mg/kg CsA is recommended for minimizing the risk of AEs [EL1]. *Pneumocystis jiroveci* prophylaxis is recommended in patients on combined immunosuppressive therapy [EL1].*

Statement 32

CsA may be administered during pregnancy in cases of severe refractory IBD as a rescue therapy [EL4]. CsA is secreted to some extent into breast milk but is likely to be safe to infants. Nonetheless breastfeeding should be discouraged due to the potential immunosuppressive effects on the newborn [EL4].

9. TNF α antagonists

TNF α antagonists authorized for treating IBD in Italy currently include infliximab (i.v.), adalimumab (s.c.) and, more recently, golimumab (s.c.) and infliximab biosimilars (i.v.).

Infusion and injection site reactions

Infusion reactions to infliximab present as a wide range of signs and symptoms within 2 hours of administration (274). These reactions are more frequently observed in clinical trials (7%-10%) (27,275,276) than in clinical practice (3.8%-10%) (277-281). Mild-moderate reactions to infliximab resolve spontaneously when the infusion is slowed or stopped. Severe reactions occur in $\leq 5\%$ of patients (282), may be life-threatening, and are more frequent during episodic than scheduled maintenance regimens (282-286).

Infusion reactions are more frequent in patients with anti-infliximab antibodies. In a meta-analysis (287), the pooled relative risk (RR) was 2.4 and the NNH was 6. However, data are conflicting, possibly due to different tests for anti-infliximab antibodies (288,289). Most of the severe reactions appear unrelated to IgE-mediated mechanisms but to anti-infliximab IgG (282,290,291). The risk of reaction is higher during re-initiation therapy (291).

Measuring levels of anti-infliximab antibodies before infliximab re-induction is of limited utility, as seronegativity does not exclude reactions (282,292). Whether concomitant immunosuppressive use prevents the development of anti-infliximab antibodies is debated (277,278,281,282,292). In patients who tolerate 2-h infliximab infusions, a 1-h infusion appears safe (293). Reactions are successfully treated using antihistamines, acetaminophen or corticosteroids. Steroid premedication and

antihistamine treatment reduce anti-infliximab antibody levels, but do not prevent reactions (294,295). Patients with mild-moderate reactions can be retreated using premedication (steroids and antihistamines) (279). Severe reactions require careful reconsideration regarding the risks and benefits of infliximab.

Adalimumab and golimumab cause mild-moderate injection site reactions at a variable frequency (4%-38%) (28,296-299). Severe systemic hypersensitivity is rare (278,300-302). Recently, golimumab was shown to have the same safety profile as other TNF α antagonists (278,298,299,302). Infliximab biosimilars and infliximab have the same type and frequency of local and systemic AEs (302-308).

Autoimmunity and delayed hypersensitivity reactions

Delayed hypersensitivity reactions (DHR) or, more appropriately, “serum sickness-like reaction”, are myalgia, arthralgia, fever or rash occurring within 14 days of infliximab administration (274,309). In clinical trials, severe DHR were reported in 0.8% (27) and 3% (275) of patients. In retrospective studies, a higher occurrence has been reported (2.8%-7%), generally after infliximab discontinuation over 12 weeks (277,287). The role of anti-infliximab antibodies in DHR is debated (281,310). Only a minority of patients with DHR underwent infliximab retreatment (281,310). Patients with severe reactions to infliximab require steroids, paracetamol and antihistamines, which lead to resolution within 1-2 weeks (6).

Skin reactions

Skin reactions associated with anti-TNF α treatment occur in about 1.5% of patients and include microbial eczema, pityriasis versicolor, herpes simplex reactivation, tinea corporis, and acute staphylococcal infection (311). Acute reactions at the injection site or after infusion are as frequent as 1% (312).

ANA seroconversion occurs in around 1% of IBD patients using anti-TNF α ; this rate is lower than that observed in similarly treated patients with rheumatoid arthritis (312). Drug-induced systemic lupus erythematosus may also occur: this syndrome cannot be prevented, but it is self-limiting in 94% of cases (313).

It has been known for a long time that the prevalence of psoriasis is higher in IBD patients than in the general population (314). These two diseases share a common genetic background (315). Paradoxical skin inflammation with “de novo” development of psoriasis has been observed in patients using TNF α antagonists (316-325), with reported incidences of 1/1,000 patient-years (324) and around 3% (325-327). Psoriasiform skin reactions show a specific immunologic pattern (328) and respond to ustekinumab (328). Dermatologic assessment is advisable.

Other rarer dermatological reactions associated with anti-TNF α treatment are alopecia, lichenoid reactions, eczema, vitiligo, acneiform eruptions, vasculitis, granuloma annulare, and interstitial granulomatous dermatitis (311,329).

Rare AEs

Non-infectious hepatitis, sometimes diagnosed as autoimmune hepatitis, is rare and mostly observed in rheumatological or dermatological diseases (330-334). TNF α antagonists may improve hepatic function in IBD patients (338). Liver deterioration during anti-TNF α treatment is more likely related to worsening of the underlying hepatic disease (338).

Occasionally, bone marrow toxicity (neutropenia, thrombocytopenia and anemia) may occur during anti-TNF α treatment. Transient neutropenia has been reported in up to 16% of patients (336,337). Increased hemoglobin levels have also been reported (338,339). TNF α antagonists may cause neurologic symptoms related

to demyelination (342-344) and worsening of preexisting multiple sclerosis (342-344). The relationship between neuropathies and TNF α antagonists is not defined.

Safety of switching therapies

Switching between anti-TNF α agents is frequently done when a patient stops responding to one agent. No specific safety concerns have been reported regarding this practice (345). Some AEs are “class effects” common to all anti-TNF α agents, and therefore recur after the switch.

Laboratory testing during treatment

No specific recommendations have been established for biochemical monitoring during anti-TNF α treatments (36,346-349). We suggest that, in the absence of signs or symptoms requiring specific investigations, full blood count, liver function tests, and laboratory tests for serum C-reactive protein, creatinine and ferritin should be done every 2-3 months. HBV-DNA should be monitored in patients with a possible occult HBV infection, while HIV re-testing is indicated for patients at risk. Screening for *C. difficile* is recommended at every flare. Patients traveling to endemic areas should be rescreened for latent tuberculosis when they return (350).

Opportunistic infections

In rheumatoid arthritis, TNF α antagonists are associated with an increased risk of opportunistic and serious infections (351-354). In CD, a 2-fold increased risk of opportunistic infections and an increased risk of serious infections (albeit lower than that observed with corticosteroids) have been reported (355-357). Age is an independent risk factor (358-360).

The risk of post-operative infectious complications using TNF α antagonists is debated. Some studies and meta-analyses showed an increased risk (especially in

CD) (361-363), while others did not, emphasizing other risk factors, including steroid use and low serum albumin (364-366).

TNF α antagonists and cancer risk

The cancer risk using anti-TNF α treatments has been extensively investigated (367-404), but several issues are still debated.

For lymphoma, the FDA reported a standardized incidence ratio (SIR) for non-Hodgkin's lymphoma of 6.4 using infliximab and 5.5 using adalimumab (368). In CD, values of SIR between 3.23 and 5.5 have been reported (369, 370). However, the lymphoma risk may be higher in subgroups of patients, particularly those with CD (371), although with conflicting evidence (372,373). As TNF α antagonists are frequently combined with thiopurines, increasing the lymphoma risk, the risk associated with anti-TNF α monotherapy is difficult to estimate (206,374). Recently, TNF α inhibitors, when used alone without thiopurines, were reported to not increase the lymphoma risk (375-379). Hepatosplenic T-cell lymphoma (HSTCL) has been reported in IBD patients, particularly young men with CD treated with combined thiopurines and TNF α antagonists (380-382). Rare cases of HSTCL were reported in patients using azathioprine, but not anti-TNF α monotherapy (see Section 10) (380-382).

Regarding NMSC, conflicting results exist on the risk in rheumatoid arthritis patients using TNF α antagonists (383-386). In IBD, a recent meta-analysis reported a 37% excess risk of melanoma (387). An excess risk of both melanoma (RR=1.29) and NMSC (RR=1.46) was observed in a large cohort of IBD patients in the United States (388). A Cochrane meta-analysis (389) and an evaluation of the TREAT registry (390) both found no increased rate of skin cancer in IBD patients treated with anti-TNF α . However, using TNF α antagonists appeared to increase the melanoma

risk (OR 1.88) (388). Similarly, a systematic review reported a 2-fold risk of NMSC in patients using anti-TNF α monotherapy (391).

Some studies have assessed the overall risk of cancer associated with anti-TNF α use. A meta-analysis of rheumatoid arthritis patients (392) found an overall increased cancer risk (RR=3.3), but this finding has not been confirmed by meta-analyses (388, 393) and treatment registries (394,395). In IBD, no increased risk of malignancy using TNF α inhibitors vs. placebo was detected in a meta-analysis of 10 trials (396). Regarding the cancer risk in the long-term, the TREAT registry, which included over 6,000 CD patients followed for >5 years, detected no difference in the unadjusted incidence of neoplasia between patients treated with infliximab and other therapies (355,397). Similarly, a retrospective analysis of four data sets from the United States did not detect an association between TNF α inhibitors and malignancy among 6,357 IBD patients (398). An Italian multicenter long-term matched pair study reported comparable frequencies of neoplasia in CD patients treated or not with infliximab (399,400). These observations have been confirmed by several studies and meta-analyses (401-403), indicating that anti-TNF α monotherapy does not increase the overall cancer risk.

More information on the risk of cancer in CD and UC patients treated with TNF α antagonists comes from a recent multicenter nested case-control study conducted by the IG-IBD (404). This study found that, in CD, the combined use of TNF α antagonists and thiopurines was a risk factor for cancer overall (OR 1.97) and for extracolonic cancer (OR 2.15). It also found that penetrating disease was a risk factor for cancer overall and for extracolonic cancer. In UC patients, immunomodulators were not identified as risk factors for cancer, while clinical characteristics did associate with cancer risk.

Pregnancy and breastfeeding

Infliximab, adalimumab and golimumab are FDA pregnancy category B drugs (Table 2). However, they cross the placenta, especially in the second and third trimesters (405,406), and detectable serum levels can persist in newborns up to 6 months after birth.

No increased risk of congenital abnormalities has emerged in several cases series and patient registries (407-415).

A recent prospective study of women TAKING anti-TNF α treatments during pregnancy reported comparable rates of infection, allergies, eczema and adverse reactions to vaccines in the newborn infants of both mothers who stopped treatment in the third trimester and those who continued (416). These rates were also similar to those in children of non-IBD women at the 1-year follow-up (416).

LIVE vaccines (poliovirus, rotavirus, BCG) should be avoided in children with in utero exposure to biologics until at least 6 months of life (416). However, a recent prospective study found that, when women were treated with adalimumab or infliximab during pregnancy, the anti-TNF α agent was detected in their infants until 12 months of age (415). Combined treatment with anti-TNF α and thiopurines during pregnancy increased the risk of infant infections beyond that associated with anti-TNF α monotherapy, suggesting that the administration of live vaccines should be avoided until the infants are older than 1 year (415).

Statement 33

Infusion-related reactions to infliximab are common but are less frequent during scheduled maintenance regimens than episodic regimens. Severe reactions are uncommon but may lead to treatment discontinuation [EL1]. Pretreatment with antihistamines or steroids does not prevent the development of infusion reactions

[EL2]. Injection site reactions to adalimumab and golimumab are usually mild and do not require drug discontinuation [EL2].

Statement 34

The most common cutaneous AEs of anti-TNF treatments are skin infections [EL2] and psoriatic manifestations [EL2]; much rarer are drug-induced systemic lupus erythematosus [EL3] and other dermatological conditions.

Statement 35

Rare potential AEs of anti-TNF agents are non-infectious hepatitis [EL4] and reduced blood cell counts (anemia, neutropenia, thrombocytopenia) [EL4].

Statement 36

Although neurological AEs associated with anti-TNF α treatment are rare, it is important to monitor signs and symptoms suggestive of a demyelinating disorder [EL5]. Patients with a history of demyelinating disease or with symptoms of polyneuropathy should be carefully evaluated before initiating anti-TNF α therapy [EL5].

Statement 37

When switching from one anti-TNF treatment to another due to loss of response, there are no additional safety concerns [EL1]. In case of anti-TNF class AEs, switching should be avoided as the risk of recurrence of the AE will be the same [EL5].

Statement 38

During anti-TNF α therapy, even in absence of alarming signs and symptoms, periodic laboratory investigations are advisable depending on the patient's conditions and risk factors [EL5].

Statement 39

Data from registries and RCTs indicate a significantly increased risk of opportunistic infections with anti-TNF α therapy [EL1]. Older age is an independent risk factor [EL3]. Data on the risk of postoperative infections are conflicting, but most series demonstrated an increased risk in CD [EL2].

Statement 40

Anti-TNF α agents used in monotherapy do not seem to increase the rate of lymphoma, including hepatosplenic T-cell lymphoma, in adults or children [EL1].

Statement 41

Data on the risk of skin cancer in IBD are limited, conflicting, and complicated by confounders (e.g. thiopurine use). However, an up to 2-fold increase in melanoma and NMSC has been reported, requiring vigilance and regular skin examinations [EL2].

Statement 42

Although long-term studies in IBD are few, no clear overall increased risk of solid malignancy has been reported during anti-TNF α therapy [EL1].

Statement 43

The use of anti-TNF α agents during pregnancy presents a low risk, but these drugs should be withdrawn in the third trimester [EL2]. Due to potential presence of these drugs in breast milk, physicians should discuss the risks of breastfeeding with mothers [L5]. LIVE vaccines in newborns with in utero exposure to biologics should be avoided for at least 6 months of life [EL2].

10. Combination therapy

Infusion reactions

Patients treated with infliximab may develop specific antibodies to this drug (417), but this risk can be reduced by adding a thiopurine (275,276). Whether concomitant immunosuppression reduces the frequency of infusion reactions is debated (278,281, 282).

Infections

Immunomodulators increase the risk of infections. Corticosteroids have been associated with fungal infections, thiopurines with viral infections, and anti-TNF α with fungal and mycobacterial infections (417). When these treatments are combined, the frequency of infections may increase. Combined immunomodulators HAVE been associated with an increased risk of opportunistic infections: 3-fold increased risk using 1 immunomodulator and 14.5-fold using ≥ 2 immunomodulators (268).

Cancer risk

A pooled analysis of clinical trial data from 1594 CD patients treated with adalimumab found a greater overall incidence of malignancy (SIR 3.04) and a higher incidence of NMSC (SIR 4.59) in patients using combined thiopurine and adalimumab (but not adalimumab monotherapy) than in the general population (418). Additionally, patients who received combination therapy had an overall higher risk of malignancy (RR=2.82) and of NMSC (RR=3.46) than did patients on adalimumab monotherapy. Only 2 cases of lymphoma were recorded in the combined series (418). These results on the safety of adalimumab monotherapy must be considered in light of several limitations of the analyzed data, namely: a) the absence of a group using immunomodulators as monotherapy; b) the non-IBD population is an imperfect

comparator for IBD patients treated with 1-2 immunomodulators; and c) immunomodulator use was defined only at baseline (possibly underestimating the cancer risk).

Our recent multicentre nested case-control study (404) found an increased overall cancer risk in patients using combination therapy with thiopurines and TNF α antagonists. This increase was greatest in patients with perforating CD (404). In contrast, an analysis of the TREAT registry showed that there was no increase in cancer risk using immunomodulators, infliximab, or combination therapy (397). Long-term multicenter studies are required to clarify this issue.

In 2009, a meta-analysis of 8,905 CD patients treated with anti-TNF α , with or without thiopurines, concluded that although combination therapy increased the risk of non-Hodgkin's lymphoma, the absolute rate is low and should be weighed against the drugs' efficacy (370). In 2011, a US study of >15,000 IBD patients confirmed that combined anti-TNF α and thiopurines, but not IBD itself, increases the lymphoma risk (381). The most common lymphoma subtypes were diffuse large B-cell lymphoma (44%), follicular lymphoma (14%), and Hodgkin's lymphoma (12%). A French study reported a higher RR of lymphoma in patients using combination therapy than anti-TNF α monotherapy (418). However, no study directly compared the lymphoma risk from combination therapy with that from anti-TNF α monotherapy.

The occurrence of HSTCL has been reported in IBD patients treated with combined thiopurines and TNF α antagonists, particularly in young (<35 years) men with CD (347,371,382,419-422). According to a systematic review published in 2011 (381), more than 10% of the approximately 200 cases of HSTCL described worldwide had been reported in IBD patients, all treated with immunomodulators (n=36). All 36 IBD patients who developed HSTCL had a history of thiopurine use, 16

as monotherapy and 20 in combination with TNF α inhibitors. No HSTCL case has been observed among IBD patients using anti-TNF α monotherapy (381,382). Among the 36 IBD patients discussed in the review (381), 27 had CD, 29 were male, their median age at diagnosis of HSTCL was 22 years, 37 were deceased at the time of the study, and the median duration of thiopurine exposure was about 5 years (range, 1-7). These data strongly support the use of combination therapy in carefully selected patients and only when a clear benefit is expected, particularly in young male CD patients. They also support the avoidance of early combined treatment in young IBD patients and the shift to thiopurines or TNF α antagonists, according to response (379,423).

Thiopurines (but not TNF α antagonists) appear to increase the risk of NMSC, particularly in patients with CD, which itself increases risk of this skin cancer (432). A nested case-control study failed to show a further increased risk in IBD patients with recent or persistent combination therapy (393). An analysis of the FDA Adverse Event Reporting System found that both anti-TNF- α monotherapy and combination therapy with thiopurines increase the risk of melanoma and NMSC in IBD patients (424). Dermatologic screening has been suggested for all patients undergoing anti-TNF α treatment (425,426). A meta-analysis of 14,590 IBD patients from 49 RCTs of biologics (adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab) reported a moderately increased risk of any infection (OR [95% CI]: 1.19 [1.10–1.29]) and a substantially increased risk of opportunistic infections (OR 1.90 [1.21-3.01]) using these drugs (302). Differently, no increased risk of serious infections or malignancy (OR 0.90 [0.54-1.50]) was found (302).

Findings from a recent meta-analysis of 16 studies suggested similar rates of cancer recurrence among individuals with prior cancer treated or not with anti-TNF

monotherapy, immunomodulators, or combined treatments (427). Additional large, prospective studies are required to clarify this relevant issue.

Statement 44

Concomitant use of immunomodulators reduces the development of anti-infliximab antibodies [EL1]. The role of concomitant immunosuppression is controversial even if it seems to reduce drug reactions during infliximab infusion [EL1].

Statement 45

The risk of opportunistic infections is higher in patients treated with combinations of immunomodulators and anti-TNF agents [EL1]. It is not clear whether this risk is related to the biologics, to the immunomodulators, to both, or to other factors such as the severity of disease [EL3].

Statement 46

The overall risk of lymphoma appears to be increased in patients treated with anti-TNF agents in combination with thiopurines [EL1], although the absolute risk is very low [EL1]. Combined treatment with thiopurines and adalimumab is associated with an increased risk of NMSC and other cancers [EL2]. Combined maintenance treatment with anti-TNF agents and thiopurines should be avoided, particularly in young patients, because of the risk of hepatosplenic T-cell lymphoma [EL4]. Combination therapy should be reserved for high-risk patients. Whether a previous history of cancer is a contraindication for combination therapy is controversial. In these patients, the decision should be made on a case-by-case basis [EL5]. The implementation of conventional screening tests, like those

commonly used before the administration of anti-TNF monotherapy, is recommended before the prescription of combination therapy [EL5].

11. Vedolizumab

Vedolizumab is a new immunomodulator effective in moderate-severe IBD (34,428,429). In Italy, vedolizumab was approved in 2016. Vedolizumab binds to $\alpha 4\beta 7$ integrin, and subsequently inhibits leukocyte adhesion and migration from the vascular endothelium into the diseased gut. Current data support the safety of vedolizumab in IBD patients (426,430-433). Low frequencies of serious infections, infusion-related reactions, malignancies and other AEs have been observed with vedolizumab (430-433). However, a longer follow up is required. Several trials (34,428,429,434) and meta-analyses (426,435) support the favorable risk profile of vedolizumab, with no increased incidence of serious AEs or serious infections compared with placebo. A low frequency (<6%) of AEs has been reported, including: headache, nasopharyngitis, nausea, arthralgia, upper respiratory infection and fatigue (431). Therefore, vedolizumab use has been suggested for elderly IBD patients, who are at higher risk of infectious complications (436). Vedolizumab use was not associated with progressive multifocal leukoencephalopathy (433), caused by JC virus reactivation, differently from natalizumab, a nonspecific antagonist of $\alpha 4\beta 7$ and $\alpha 4\beta 1$ integrins (437). The FDA classifies vedolizumab in pregnancy category B (Table 2).

Appendix

List of attendees: Annalisa Aratari, Aurora Bortoli, Fabrizio Bossa, Maria Cappello, Andrea Cassinotti, Alberto Chiriatti, Gionata Fiorino, Vincenzo Formica, Luisa Guidi, Alessandra Losco, Filippo Mocchiato, Sara Onali, Luca Pastorelli, Roberta Pica, Mariabeatrice Principi, Sara Renna, Chiara Ricci, Antonio Rispo, Francesca Rogai, Loredana Sarmati, Franco Scaldaferrri, Luisa Spina, Rosy Tambasco, Anna Testa, Angelo Viscido.

CONFLICT OF INTEREST**First authors:**

L. Biancone Lecture fees: MSD, Takeda, Abbvie, Zambon. Mundipharma,
Wasserman

G. Meucci. None declared

References

1. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterology* 1979;77:847–69.
2. Malchow H, Ewe K, Brandes JW, et al. European Co-operative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterology* 1984;86:249–66.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955;2:1041–8.
4. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. *J Clin Gastroenterol* 1990;12:40–1.
5. Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. *Am J Gastroenterol* 2007;102:601–8.
6. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohns Colitis* 2010;4:28–62.
7. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis*. 2012;6:991-1030.
8. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. *J Clin Gastroenterol* 1994;19:278–82.
9. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. *Gastroenterology* 1993;104:1293–301

10. Cortot A, Colombel JF, Rutgeerts P. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. *Gut* 2001;48:186–90.
11. Sandborn WJ, Löfberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. *Am J Gastroenterol* 2005;100:1780-7.
12. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. *Aliment Pharmacol Ther* 2003;17:1471-1480.
13. Sutherland LR, Singleton J, Sessions J, et al. Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. *Gut* 1991;32:1071–5.
14. Colombel JF, Lemann M, Cassagnou M, et al. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. *Am J Gastroenterol* 1999;94:674–8.
15. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. *Am J Gastroenterol* 1996;91:328–32.
16. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. *Gut* 1995;37:674–8.
17. Lémann M, Mary JY, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. *Gastroenterology* 2005;128:1812–8.
18. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. *Lancet* 1971;ii:944–7.

19. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. *Am J Dig Dis* 1975;20:721–6.
20. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. *Lancet* 1978;ii:955–97.
21. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. *N Engl J Med* 2000;342:1627–32.
22. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. *Gastroenterology* 2001;120:1323–9.
23. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. *Gastroenterology* 2003;125:1025–31.
24. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). *Gastroenterology* 1995;109:129-35.
25. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997;337:1029–35.
26. Schnitzler F, Fidler H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. *Gut* 2009;58:492–500.
27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005;353: 2462–76.

28. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 2006;130:323–33.
29. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. *Ann Intern Med* 2007;146:829–38.
30. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2012;142:257–65.
31. Sandborn WJ, Feagan BG, Marano C, et al. PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146: 85-95.
32. Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF infliximab biosimilars in inflammatory bowel diseases. *Aliment Pharmacol Ther* 2015 ;42(10):1158-69.
33. Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. *Autoimmun Rev.* 2014;13:751-5.
34. Feagan B, Rutgeerts P, Sands B, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 369: 699–710.
35. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. *Inflamm Bowel Dis* 2010;16:112–24.

36. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. *Dig Liver Dis* 2011;43:1-20.
37. OCEBM Levels of Evidence Working Group. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/index.aspx?o=5653>.
38. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. *Acta Med Scand* 1942;110:557–90.
39. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. *Lancet* 1977; 2: 892–5.
40. Loftus EV JR, Kane SV, Bjorkman D. Systematic review: short term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. *Aliment Pharmacol Ther* 2004;19:179–189.
41. Feagan BG, MacDonald JK. Oral aminosalicylic acid for induction of remission in ulcerative colitis (Review). *The Cochrane Library* 2012, Issue 10.
42. Feagan BG, Chande N, MacDonald JK. Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. *Inflamm Bowel Dis* 2013;19:2031-40.
43. Kamm MA, Sandborn WJ, Gassull M, et al. Once daily, high concentration MMX mesalamine in active ulcerative colitis. *Gastroenterology* 2007;132:66–75.

44. Netzer P. Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease. *Schweiz Med Wochenschr.* 1995 Dec 16;125(50):2438-42
45. Watkinson G. Sulphasalazine: a review of 40 years' experience. *Drugs* 1986;32 (suppl 1):1-11
46. Poland GA, Love KR. Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy. *Am J Med* 1986;81:707-708.
47. Mihas AA, Goldenberg DJ, Slaughter RL. Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes. *JAMA* 1978;239:2590-2591.
48. Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and neurotoxicity following sulphasalazine administration. *Aust N Z J Med* 1982;12:76-80.
49. Han T, Chawla PL, Sokal JE. Sulfapyridine-induced serum sickness-like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gammaglobulinopathy. *N Engl J Med* 1969;280:547-548.
50. Tisdale WA. Focal hepatitis, fever and skin rash following therapy with sulfamethoxypyridazine, a long-acting sulfonamide. *N Engl J Med* 1958;258:687-690.
51. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. *Int Surg* 1985;70:271-272.
52. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. *Am J Gastroenterol* 1994;89:789-791.
53. Garau P, Orenstein SR, Neigut DA, et al. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis. *J Pediatr Gastroenterol Nutr* 1994;18:481-485.

54. Debongnie JC, Dekoninck X. Sulfasalazine, 5-ASA and acute pancreatitis in Crohn's disease. *J Clin Gastroenterol* 1994;19:348–349
55. Munk EM, Pedersen L, Floyd A, Norgard B, et al. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. *Am J Gastroenterol* 2004; 99: 884–8.
56. Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. *Aliment Pharmacol Ther* 2003; 17: 887–93
57. Douros A, Bronder E, Andersohn F, et al. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases. *Aliment Pharmacol Ther* 2013;38:825–834.
58. Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. *Gastroenterology*. 1980;78:813–820.
59. Block MB, Genant HK, Kirsner JB. Pancreatitis as an adverse reaction to salicylazosulfapyridine. *N Engl J Med* 1970;282:380–382.
60. Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. *N Engl J Med* 1973;289:491–495.
61. Daneshmend TK. Mesalazine associated thrombocytopenia. *Lancet* 1991;337:1297–8.
62. Casellas F, Vallano A, Malagelada JR. Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories. *J Clin Gastroenterol* 1996; 22:160–1
63. Wyatt S, Joyner MV, Daneshmend TK. Filgastrim for mesalazine-associated neutropenia. *Lancet* 1993;341:1476.

64. Turunen U, Elomaa I, Anthla VI, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. *Scand J Gastroenterol* 1987;22: 798–802.
65. Laidlaw ST, Reilly JT. Antilymphocyte globulin for mesalazine-associated aplastic anemia. *Lancet* 1994;343:981-2.
66. Abboudi ZH, Marsh JC, Smith-Long G, et al. Fatal aplastic anemia after mesalazine. *Lancet* 1994;343(8896):542 (letter).
67. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. *Gastroenterology* 2005;129:827-36.
68. Ishikawa N, Imamura T, Nakajima K et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis. *Intern Med* 2001;40:901-4.
69. Sentongo TA, Piccoli DA. Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. *J Pediatr Gastroenterol Nutr* 1998;27:344-7.
70. Perrot S, Aslangul E, Szwebel T, et al. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine. *Int J Colorectal Dis* 2007;22:1119-21.
71. Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. *Rev Gastroenterol Disord* 2004;4(2):86-91.
72. Di Paolo MC, Paoluzi OA, Pica R, et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. *Dig Liver Dis* 2001;33(7):563-9.

73. Heap GA, So K, Weedon M, Edney N. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. *J Crohns Colitis*. 2016;10:149-58
74. Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. *Aliment Pharmacol Ther* 2005;21:1217–24.
75. Dehmer C, Greinwald R, Löffler J. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. *Int J Colorectal Dis*. 2003;18:406-12.
76. Elseviers MM, D'Haens G, Lerebours E et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? *Clin Nephrol* 2004;61:83–9.
77. Travis SP, Stange EF, Lemann M et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. *J Crohns Colitis* 2008;2:24–62.
78. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010;105:501–23.
79. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. *Gastroenterology* 2004;126:1733–9
80. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. *Aliment Pharmacol Ther* 2000;14:1–6.
81. World MJ, Stevens PE, Ashton MA et al. Mesalazine associated interstitial nephritis. *Nephrol Dial Transplant* 1996;11:614–21.

82. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. *Aliment Pharmacol Ther* 2002;16:647–62.
83. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. *Inflamm Bowel Dis* 2007;13: 629-638.
84. Sannerstedt, R. Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. *Drug Saf* 1996;14(2): 69-77.
85. Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. *Aliment Pharmacol Ther* 1998;12:1101-8.
86. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. *Gastroenterology* 1998;114:23-8.
87. Marteau P, Devaux CB. Mesalazine during pregnancy. *Lancet* 1994;344:1708-9.
88. Sachar D. Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight. *Gut* 1998;43:316.
89. Nørgård B, Fonager K, Pedersen L, et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. *Gut* 2003;52:243-7.
90. Nørgård B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. *Am J Gastroenterol* 2007;102:1406-13.
91. Ban L, Tata LJ, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. *Gastroenterology* 2014;146:76-84.

92. Marteau P, Seksik P, Couve S, et al. Safety of high doses of mesalazine during pregnancy. *Am J Gastroenterol* 2005;100:1897-8.
93. Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. *Reprod Toxicol* 2008;25:271-5.
94. Moffatt DC, Bernstein CN. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. *Best Pract Res Clin Gastroenterol* 2007;21:835-47.
95. Position paper Agenzia Italiana per il Farmaco (AIFA), 2013
96. Peppia M, Krania M, Raptis SA. Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. *2011 Integr Blood Press Control* 2011;4:7-16
97. Whitworth JA, Williamson PM, Mangos G et al. Cardiovascular consequences of cortisol excess. *Vasc Health Risk Manag.* 2005;1:291-299
98. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis.* 2006; 65:285-293
99. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2010 Oct 6;(10):CD007698.
100. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology.* 2008;134:929-936
101. Rahier JF, Magrob F, Abreue C, et al Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic

- infections in inflammatory bowel disease *Journal of Crohn's and Colitis* 2014; 8: 443–468
102. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int.* 2002; 13:777-787
103. Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos.* 2011; 6:59-155.
104. Hauzeur J, Malaise M, Gangji V. Osteonecrosis in inflammatory bowel diseases: a review of the literature *Acta Gastroenterol Belg.* 2009;72:327-334.
105. Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. *Am J Gastroenterol.* 2008; 103:2373-81.
106. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. *Gastroenterology* 2003;125:320–327
107. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. *Infl Bowel Dis* 2009;15:1062-1070
108. van der Woude CJ, Sanja Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease *J Crohns Colitis* 2010;4:493–510
109. Bortoli A, Pedersen N, Duricova D, et al Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. *Aliment Pharmacol Ther* 2011;34:724-34.

110. Day AC, Baio G, Gazzard G, et al The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. *Br J Ophthalmol* 2012;96:1162-1167.
111. Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. *Expert Opin Drug Saf.* 2016;15(4):457-65.
112. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol* 2006;4:621-630.
113. Fascì Spurio F, Aratari A, Margagnoni G, et al. Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter? *J Gastrointestin Liver Dis* 2013;22:65-71.
114. D'Haens GR, Kovács A, Vergauwe P, et al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. *J Crohns Colitis* 2010;4:153-160.
115. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. *N Engl J Med* 1994;331: 836-841.
116. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. *Am J Gastroenterol* 2002;97: 1748-1754.
117. Tromm A, Bunganič I, Tomsová E, et al. International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. *Gastroenterology* 2011;140: 425-434.e1.

118. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. *N Engl J Med* 1998;339: 370-374. Erratum in: *N Engl J Med* 2001;345: 1652.
119. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. *N Engl J Med* 1994;331: 842-845.
120. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. *Eur J Gastroenterol Hepatol* 1996;8: 905-909.
121. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. *Gut* 1997;41: 209-214.
122. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. *Gastroenterology* 1998;115:835-840.
123. Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. *Eur J Gastroenterol Hepatol* 2004;16:47-54.
124. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. *Gastroenterology* 2012;143:1218-1226.

125. Travis SP, Danese S, Kupcinkas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut* 2014;63:433-41.
126. Gross V, Bunganic I, Belousova EA, et al. 3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. *J Crohns Colitis* 2011;5:129-138.
127. Löfberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. *Gastroenterology* 1996;110:1713-1718.
128. Lichtenstein GR, Travis S, Danese S, et al. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. *J Crohns Colitis* 2015;9:738-46.
129. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2011;106: 590-99.
130. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. *Aliment Pharmacol Ther* 2002;16:1109-1116.
131. Van Assche G, Manguso F, Zibellini M, et al. Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study. *Am J Gastroenterol* 2015;110:708–715.
132. Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study.

- Canadian Inflammatory Bowel Disease Study Group. *Gastroenterology* 1996;110:45-51.
133. Löfberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. *Gut* 1996;39:82-86.
134. Gross V, Andus T, Ecker KW et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. *Gut* 1998;42:493-96.
135. Hanauer S, Sandborn WJ, Persson A et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. *Aliment Pharmacol Ther* 2005;21:363-71
136. Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2014 Aug 21;8:CD002913.
137. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. *Gastroenterology* 1999;116:294-300
138. Ewe K, Böttger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. *Eur J Gastroenterol Hepatol* 1999;11: 277-82.
139. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. *Clin Gastroenterol Hepatol* 2005;3:113-21

140. Prantera C, Rizzi M, Cottone M, et al. Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial. *Dig Liver Dis* 2011;43:459-64.
141. D'Haens G, Verstraete A, Cheyngs K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. *Aliment Pharmacol Ther* 1998;12:419-24.
142. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. *Am J Gastroenterol* 2002; 97:915-21.
143. Lichtenstein GR, Bengtsson B, Hapten-White L, et al. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. *Aliment Pharmacol Ther* 2009 Mar 15;29:643-53.
144. Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. *Inflamm Bowel Dis*. 2009;15:25-8.
145. Christensson C, Thorén A, Lindberg B. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. *Drug Saf*. 2008;31: 965-88.
146. de Aguiar MM, da Silva HJ, Rizzo JA et al. Inhaled beclomethasone in pregnant asthmatic women - A systematic review. *Allergol Immunopathol* 2014;42: 493-99.
147. Powrie RO, Larson L, Miller M. Managing asthma in expectant mothers. *Treat Respir Med* 2006;5:1-10.
148. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. *Nat Rev Gastroenterol Hepatol* 2014;11: 116-27.
149. Van Assche G, Dignass A, Reinisch W, et al. European Crohn's and Colitis

- Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. *J Crohns Colitis* 2010; 4: 63-101.
150. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: special situations. *J Crohns Colitis* 2013; 7:1-33.
151. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. *Clin Infec Dis* 1999; 28:299-308.
152. Owens R, Ambrose P. Antimicrobial safety: focus on fluoroquinolones. *Clin Infect Dis* 2005; 41 Suppl 2:S144-57.
153. Issa M, Vijayapal A, Graham MB, et al. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007; 5: 345-51.
154. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathological features of fluoroquinolone-induced liver injury. *Clin Gastroenterol Hepatol* 2011;9:517-23.
155. Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. *Drug Saf* 2011;34:465-88.
156. Melhus A. Fluoroquinolones and tendon disorders. *Expert Opin Drug Saf* 2005; 4:299-309.
157. Adefurin A, Sammons H, Jacqz-Aigrain E, et al. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011;96:874-80.
158. Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of achilles tendon disorders: case-control study. *BMJ* 2002;324:1306-7.

159. Arabyat RM, Raisch DW, McKoy JM, et al. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. *Expert Opin Drug Saf* 2015; 14:1653-60.
160. Prabhakar M, Khran AD. Ciprofloxacin-induced acquired long QT syndrome. *Heart Rhythm* 2004;1:624-6.
161. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. *Gastroenterology* 1995;108:1617-21.
162. Karamanakos PN, Pappas P, Boumba VA, et al. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. *Int J Toxicol* 2007;26:423-32.
163. Smith JA. Neutropenia associated with metronidazole therapy. *Can Med Ass J* 1980; 123:202.
164. Kuriyama A, Jackson JL, Doi A, et al. Metronidazole-induced central nervous system toxicity: a systematic review. *Clin Neuropharmacol* 2011; 34: 241-7.
165. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn's disease with metronidazole. *Gastroenterology* 1980; 79: 357-65.
166. Jacobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. *Am J Gastroenterol* 1984;79:533-40.
167. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. *Drugs* 1995;49:467-84.
168. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. *Chemotherapy* 2005; 51(suppl 1):36-66.

169. Berkovitch M, Pastuszak A, Gazarian M, et al. Safety of the new quinolones in pregnancy. *Obstet Gynecol* 1994;84:535-8.
170. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother* 1998;42:1336-9.
171. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohns Colitis* 2015;9(2):107-24
172. Mahadevan U, Kane S. American Gastroenterological Association institute technical review on the use of gastrointestinal medications in pregnancy. *Gastroenterology* 2006; 131:283-311.
173. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. *Br J Obstet Gynaecol* 1998;105:322-7.
174. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 1995;172:525-9.
175. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 1997;44:179-82.
176. Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. *Antimicrob Agents Chemother* 2012; 56:4800-5.
177. Mathew JL. Effect of maternal antibiotics on breast feeding infants. *Postgrad Med J* 2004; 80:196-200.
178. Chaparro M. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflamm Bowel Dis* 2013;19:1404-1410.

179. Saibeni S, Virgilio T, D'Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. *Dig Liver Dis* 2008; 40: 814-820.
180. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. *Inflamm Bowel Dis* 2010; 16:1541-1549.
181. Costantino G, Furfaro F, Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. *J Crohns Colitis*. 2012; 6(5):588-96
182. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. *Am J Gastroenterol* 1999;94:3254–7.
183. Bidinger JJ, Sky K, Battafarano DF, et al. The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome. *J Am Acad Dermatol*. 2011 65(1):184-91.
184. Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. *Clin Gastroenterol Hepatol* 2009; 7:1195-1201.
185. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. *Am J Gastroenterol* 2008;103:1783-1800.
186. Lennard L. The clinical pharmacology of 6-mercaptopurine. *Eur J Clin Pharmacol* 1992;43:329-39.
187. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP Resistance in Patients With Inflammatory Bowel Disease. *Gastroenterology* 2002;122:904-15.

188. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. *Lancet* 1990; 336: 225–229.
189. Gisbert JP, Niño P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. *Am J Gastroenterol* 2006;101(12):2769-76.
190. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. *Gastroenterology* 2000; 118: 705-713-
191. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. *Gut* 1996;39:401-406.
192. Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10⁸ erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. *Am J Gastroenterol*. 2008;103(12):3115-22.
193. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol* 2005;100(10):2239-47.
194. Gisbert JP, Niño P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. *Am J Gastroenterol*. 2006;101(12):2769-76.
195. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* 2011;89:387-91.

196. Zur RM, Roy LM, Ito S, et al Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy. *Pharmacogenomics J* 2016;17:633-56.
197. Palmieri O, Latiano A, Bossa F, et al Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. *Aliment Pharmacol Ther* 2007;26:737-45.
198. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. *Aliment Pharmacol Ther* 2004;20:593-9.
199. Van den Akkervan Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukaemia in Europe. *Pharmacogenomics* 2006;7:783-92.
200. Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. *Int J Technol Assess Health Care* 2008;24:294–302.
201. Preist VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. *Pharmacoeconomics* 2006;24:761–81.
202. Sayani FA, Prosser C, Bailey RJ, et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with

- azathioprine: effect on cost and adverse events. *Can J Gastroenterol* 2005; 19:147–51.
203. Bermejo F, López-Sanromán A, Algaba A, et al. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. *Aliment Pharmacol Ther* 2010; 31:120-124.
204. Kiefer K, El-Matary W. 6-mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatotoxicity. *Inflamm Bowel Dis* 2009;15:318-319.
205. Kennedy NA, Rhatigan E, Arnolti D, et al A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. *Aliment Pharmacol Ther* 2013;38 (10):1255-66.
206. Tuyama AC, Karakauer M, Alzaabi M, et al. Mercaptopurine induced hepatoportal sclerosis in a patient with Crohn's Disease. *J Chron Colitis* 2013;7:590-593.
207. Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. *World J Gastrointest Pharmacol Ther* 2014;5(2):63-76.
208. Sansone S, Guarino M, Castiglione F, et al. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. *World J Gastroenterol* 2014; 20(13):3516-24.
209. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. *Aliment Pharmacol Ther* 2002; 16:79-85
210. Daperno M, Sostegni R, Canaparo R, et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. *Aliment Pharmacol Ther* 2009; 30:843-853.

211. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2010; 31:640-647.
212. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. *J Crohns Colitis* 2010;4:444-449.
213. Vögelin M, Biedermann L, Frei P, et al. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. *PLoS One*. 2016;11(5):e0155218.
214. Teksik P, Cosnes J, Sokol H et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Aliment Pharmacol Ther* 2009, 29(10):1106-13.
215. James DG, Stone CD, Wang HL, et al. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. *Inflamm Bowel Dis* 2006; 12:573-580.
216. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in Inflammatory Bowel Disease. *Lancet* 1994;343:1249-1252.
217. Glick SN, Teplick SK, Goodman LR, et al. Development of lymphoma in patients with Crohn's disease. *Radiology* 1984;153:337-339.
218. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. *Gastroenterology*. 2013;145:1007-1015.
219. Lakatos PL, Lovasz BD, David G et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a

- population-based cohort in Eastern Europe. *J Crohns Colitis*. 2013;7:385-91.
220. Lewis J, Schwartz S, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's Disease: benefits outweigh the risk of lymphoma. *Gastroenterology* 2000; 118:1018-1024.
221. Dayharsh G, Loftus EV, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine. *Gastroenterology* 2002;122:72-7.
222. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. *Gut* 2005;54:1121-5.
223. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009; 374:1617-25.
224. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. *Inflamm Bowel Dis* 2011;17:1837-45.
225. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2010; 8: 268-74.
226. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. *J Gastroenterol Hepatol*. 2012; 27:385-9.
227. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. *Inflamm Bowel Dis* 2011;17:1423-7.

228. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology* 2011;141:1621-28.
229. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. *Am J Gastroenterol.* 2014;109:163-9.
230. Bourrier A, Carrat F, Colombel JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Aliment Pharmacol Ther* 2016;43:252-261.
231. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. *Am J Gastroenterol* 2004;99:878-83.
232. Mahadevan U, Loftus EV Jr, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. *Inflamm Bowel Dis* 2002;8:311-6.
233. Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating inflammatory bowel disease in pregnancy: the issues we face today. *J Crohns Colitis* 2015;9(10):928–936
234. Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. *Expert Rev Clin Immunol* 2010; 6: 643-57.
235. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF- α drugs during pregnancy in patients with inflammatory bowel disease. *Am J Gastroenterol* 2013;108:433-40.
236. Caprilli R, Angelucci E, Cocco A, et al. Appropriateness of immunosuppressive

- drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. *Dig Liver Dis* 2005;37:407–417.
237. Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. *Gut*. 2014 Mar; 63:451-457.
238. Teruel C, López-San Román A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. *Am J Gastroenterol* 2010; 105:2003-08.
239. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. *Am J Gastroenterol* 2000;95:684-648.
240. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013;19:15–22 .
241. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. *The New England journal of medicine*. 1995;332:292-7.
242. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev* 2013;5:CD000951.
243. Malatjalian DA, Ross JB, Williams CN et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. *Can J Gastroenterol* 1996;10:369-75.

244. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. American College of Gastroenterology. *Am J Gastroenterol* 1988;83:1337-45.
245. Soares NC, Hamlin PJ, Greer DP, et al. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. *Aliment Pharmacol Ther* 2012;35:284-91.
246. Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. *Aliment Pharmacol Ther* 2005;21:385-9.
247. Chande N, Abdelgadir I, Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn's disease. *J Clin Gastroenterol* 2011;45:599-601.
248. Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. *Inflamm Bowel Dis* 2012;18:359-67.
249. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. *Am J Gastroenterol* 2000;95:1730-4.
250. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. *Am J Gastroenterol* 2000;95:3150-6.
251. Watanabe K, Takase K, Ohno S, et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. *Mod Rheumatol* 2012;22:470-3.
252. Barbero-Villares A, Mendoza Jimenez-Ridruejo J, Taxonera C, et al. Evaluation of liver fibrosis by transient elastography (Fibroscan(R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. *Scand J Gastroenterol* 2012;47:575-9.

253. Kremer JM, Alarcon GS, Lightfoot RW Jr. et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. *Arthritis Rheum* 1994;37:316-28.
254. Powell HR, Ekert H. Methotrexate-induced congenital malformations. *Med J Aust* 1971;2:1076-7.
255. Saibeni S, Bollani S, Losco A, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. *Dig Liver Dis* 2012;44:123-7.
256. Sandborn WJ. A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 1995;1:48-63
257. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994;330:1841-5.
258. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2009;3:47-91.
259. Campbell S, Travis S, Jewell D. Cyclosporin use in acute ulcerative colitis: a long-term experience. *Eur J Gastroenterol Hepatol* 2005;17:79-84.
260. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. *Nephrol Dial Transplant*. 2007; 22 Suppl 1:i4-10.
261. Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. *J Dermatolog Treat*. 2012;23:290-304.
262. Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immune-mediated inflammatory diseases (IMID). *Mol Cancer* 2013;12:98.

263. Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. *Ann Pharmacother*. 2007;41: 21-8.
264. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348:1681-91.
265. Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. *Br J Dermatol* 2006;154:498-504.
266. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. *Lancet* 1998;351:623-8.
267. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. *Dis Colon Rectum* 2001;44:1436-40
268. Poritz LS, Rowe WA, Swenson BR, et al. Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost? *Dis Colon Rectum* 2005; 48:1685-90.
269. Costa ML, Surita FG, Passini R, et al. Pregnancy outcome in female liver transplant recipients. *Transpl Immunol* 2011;43:1337-9.
270. Millsop JW, Heller MM, Eliason MJ, et al. Dermatological medication effects on male fertility. *Dermatol Ther* 2013;26:337-46
271. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. *Inflamm Bowel Dis* 2010;16:881-95.

272. Perales-Puchalt A, Vila Vives JM, Lopez Montes J, et al. Pregnancy outcomes after kidney transplantation – immunosuppressive therapy comparison. *Matern Fetal Neonatal Med* 2012; 25:1363-6.
273. Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. *Inflamm Bowel Dis* 2009;15:1044-8.
274. Lichtenstein L, Ron Y, Kivity S et al. Infliximab-Related Infusion Reactions: Systematic Review. *J Crohns Colitis* 2015;9:806-15.
275. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;359:1541–9.
276. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004;350:876–85.
277. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. *Gastroenterology* 2004;126:19-31.
278. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. *Aliment Pharmacol Ther* 2009;29:286-297
279. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. *Am J Gastroenterol* 2003;98:1315-1324
280. Fidler H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single centre cohort study. *Gut* 2009;58:501-508.

281. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin Gastroenterol Hepatol* 2004;2:542-53.
282. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease *Aliment Pharmacol Ther* 2011;34: 51-58
283. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. *Am J Gastroenterol* 2002;97:1408-14.
284. Narula N, Kainz S, Petritsch W, et al. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF- α naïve Crohn's disease. *Aliment Pharmacol Ther.* 2016;44(2):170-80.
285. Magro F, Marques M, Santos CC. Episodic infliximab treatment induces infusion reactions. *Inflamm Bowel Dis* 2008;14: 1608-10.
286. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology* 2004; 126:402-13.
287. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with Inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2014;20:1-6.
288. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of Infliximab in Crohn's disease. *Am J Gastroenterol* 2008;103:944-8.

289. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. *Inflamm Bowel Dis* 2009;15:1264-1275
290. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. *Expert Rev Clin Immunol* 2011;7:55-63
291. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD *Aliment Pharmacol Ther* 2012;35:714-722.
292. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut*. 2007;56:1226-31.
293. Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. *Aliment Pharmacol Ther* 2013; 38: 365-376.
294. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology*. 2003;124:917-24.
295. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. *Inflamm Bowel Dis*. 2005;11:442-6.
296. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut* 2007;56:1232-9
297. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007;132:52-65

298. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146(1):85-95.
299. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146(1):96-109.
300. Mounach A, Rezqi A, Nouijai A, et al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. *Rheumatol Int* 2013; 33:1351-3.
301. Marques I, Lagos A, Reis J, et al. Reversible Henoch-Schönlein purpura complicating adalimumab therapy. *J Crohns Colitis*. 2012;6:796-9.
302. Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients with Inflammatory Bowel Disease: a Systematic Review and Network Meta-analysis. *Clin Gastroenterol Hepatol* 2016; 2016 May 14. pii: S1542-3565(16)30197-5
303. Danese S, Gomollon F, the Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). *J Crohns Colitis* 2013;7:586–9.
304. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn's Colitis Organization (ECCO) members : A updated survey. *J Crohns Colitis*. 2016 Apr 25. pii: jjw090. [Epub ahead of print]-
305. Gecse KB, Khanna R, van den Brink GR, et al. Biosimilars in IBD: hope or expectation? *Gut* 2013; 62: 803-7.

306. AIFA. Position paper su farmaci biosimilari. <http://www.agenziafarmaco.gov.it/content/position-paper-sui-farmaci-biosimilari-28052013> [28.05.13].
307. Annese V, Vecchi M. Statements of the Italian Group for Inflammatory Bowel Disease- Dig Liver Dis 2014;46:963-8.
308. Fiorino G, Annese V, et al. The PROSIT-BIO-Cohort of the IG-IBD. A prospective observational study of patients with Inflammatory Bowel Disease treated with Infliximab biosimilars. *Gastroenterology* 2016;150:S92.
- ~~309.~~ Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. *Curr Treat Options Gastroenterol.* 2014;12(1):59-75.
310. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003;348:601-8 .
311. Kerbleski JF1, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. *Gut* 2009;58:1033-9.
312. Schaible TF. Long term safety of infliximab. *Can J Gastroenterol* 2000;14(Suppl C):29C-32C
313. Ramos-Casals M, Brito-Zerón P, Soto MJ, et al Autoimmune diseases induced by TNF-targeted therapies. *Best Pract Res Clin Rheumatol* 2008;22:847-51
314. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. *Br J Dermatol* 1982;106:323-30
315. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. *Am J Hum Genet* 2012;90:636-47

316. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. *Aliment Pharmacol Ther* 2011;34:1318-27
317. Afzal A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. *J Crohns Colitis* 2014;8:480-8.
318. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. *J Crohns Colitis* 2012;6:518-23
319. Cleynen I, Moerkercke WV, Billiet T, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. *Ann Intern Med* 2016;164:10-22.
320. Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. *Am J Gastroenterol* 2015;110:1186-96.
321. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. *Dermatology* 2007;215:295-300
322. Mocchi G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. *J Crohns Colitis* 2013;7:769-79
323. Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. *Aliment Pharmacol Ther.* 2015;42:880-8.

324. Harrison MCJ, Dixon WG, Watson KD, et al. BSRBR Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2009;68:209-15
325. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthritis treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? *Rheum Dis* 2003;62:829-34.
326. Niess JH, Danese S. Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology? *Gut* 2014;63:533-5.
327. Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. *J Crohns Colitis*. 2014;8(6):480-8.
328. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2014;63:567-77.
329. Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;38:1002-24.
330. Perdani-Pirkmajer K, Hočevár A, Rotar Ž, et al. Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry. *Rheumatol Int* 2013;33:2885-8.

331. Rowe BW, Gala-Lopez B, Tomlinson C, et al. Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two. *Transpl Int* 2013;26:e110-2
332. Di Minno MN, Iervolino S, Peluso R, et al. CaRRDS Study Group. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor- α blockers. *J Rheumatol* 2012;39:1042-6
333. Poulin Y, Thérien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. *J Cutan Med Surg* 2010;14:100-4
334. Coffin CS, Fraser HF, Panaccione R, et al. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF- α) use for inflammatory bowel disease. *Inflamm Bowel Dis* 2011;17:479-84
335. Thomsen KL, Grønbæk H, Dahlerup JF, et al. Prednisolone but not infliximab aggravates the upregulated hepatic nitrogen elimination in patients with active inflammatory bowel disease. *Inflamm Bowel Dis* 2014;20:7-13
336. Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. *Aliment Pharmacol Ther* 2012;36:312-23
337. Sebastian S, Ashton K, Houston Y, et al. Anti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literature. *J Crohns Colitis* 2012;6:713-6
338. Furst DE, Kay J, Wasko MC, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Rheumatology* 2013;52:1845-55.

339. Katsanos K, Cavalier E, Ferrante M, et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. *J Crohns Colitis* 2007;1:97-105
340. Matsumoto T, Nakamura I, Miura A, et al. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. *Clin Rheumatol* 2013;32:271-5.
341. Ryu YS, Park SH, Kim JM, et al. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. *Rheumatol Int* 2012;32(11):3481-5.
342. Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. *Autoimmun Rev* 2014;13:54-8.
343. Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. *Am J Med Sci.* 2011;342:352-5.
344. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF- α), anti-TNF- α and demyelination revisited: an ongoing story. *J Neuroimmunol* 2011;234:1-6.
345. Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. *Aliment Pharmacol Ther* 2015;41:613-23.
346. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology* 2015;148(7):1320-9.
347. an Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the

- European Crohn's and Colitis Organisation: safety. *Am J Gastroenterol* 2011;106:1594-602.
348. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2011;60:571-607.
349. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF- α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology* 2013;145:1464-78.
350. Carpio D, Jauregui-Amezaga A, de Francisco R, et al. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. *J Crohns Colitis*. 2016; Jan 22. pii: jjw022. [Epub ahead of print]
351. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? *Ann Rheum Dis* 2011;70:1914-20.
352. Greenberg JD, Reed G, Kremer JM et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. *Ann Rheum Dis* 2010;69:380-6.
353. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010;69:976-86.

354. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2011;70:1810-4.
355. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. *Am J Gastroenterol* 2012;107:1409-22.
356. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor- α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2013;108:1268-76.
357. Annese V, Duricova D, Gower-Rousseau C, et al. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. *J Crohns Colitis* 2016;10:216-25.
358. Magro F, Santos-Antunes J, Albuquerque A, et al. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. *Inflamm Bowel Dis*. 2013;19(8):1710-6.
359. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2011;9:30-5.
360. Naganuma M, Kunisaki R, Yoshimura N, et al. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. *J Gastroenterol* 2013;48:595-600.

361. Serradori T, Germain A, Scherrer ML, et al. The effect of immune therapy on surgical site infection following Crohn's Disease resection. *Br J Surg* 2013;100:1089-93.
362. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. *J Crohns Colitis* 2013;7:853-67.
363. Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNF α treatment and post-operative complications in patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013;37:1057-64.
364. Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. *J Crohns Colitis.* 2013;7:868-77.
365. Ehteshami-Afshar S, Nikfar S, Rezaie A, et al. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. *Arch Med Sci* 2011;7:1000-12.
366. Huang W, Tang Y, Nong L, et al. Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn's disease: A meta-analysis of observational studies. *J Crohns Colitis* 2015;9:293-301.
367. Targownik LE, Bernstein CN. Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD- *Am J Gastroenterol* 2013;108:1835-1842.
368. <http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm>
369. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. *Am J Gastroenterol* 2011;106:2146-53.

370. Siegel CA , Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol* 2009;7:874-81 .
371. Bernstein CN, Blanchard JF, Kliever E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer* 2001;9:854-62.
372. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. *Am J Gastroenterol* 2000;95:2308-12 .
373. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. *Gastroenterology* 2001;121:1080–7.
374. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine *Gut* 2005;54:1121-5 .
375. Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case control study. *Inflamm Bowel Dis* 2013;19:1384-9.
376. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor- α antagonists and risk of cancer in patients with inflammatory bowel disease. *JAMA* 2014;311:2406-13
377. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. *N Engl J Med*. 2015;372:1441-52
378. Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. *J Crohns Colitis*. 2015;9:945-65..

379. Dulai PS, Thompson KD, Blunt HB ,et al. Risk of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. *Clin Gastroenterol Hepatol* 2014;12:1443-51
380. Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. *Crit Rev Oncol Hematol* 2012;83:283-92 .
381. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2011;9:36-41.
382. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha)inhibitors: results of the REFURBISH study. *Am J Gastroenterol* 2013;108:99-105 .
383. Askling J, Fahrbach K, Nordstrom B *et al.* Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. *Pharmacoepidemiol Drug Saf* 2011;20:119-30.
384. Le Blay P, Mouferde G, Barnetche T, et al. Risk of malignancy including non-melanoma skin cancer with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. *Clin Exp Rheumatol* 2012;30:756-64.
385. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocytes skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register- *Ann Rheum Dis* 2012;71:869-74.

386. Reachou P, Simard JF, Holmqvist M, et al. ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. *Br Med J* 2013;346:f1939.
387. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014;12:210-8.
388. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology* 2012;143:390-399.
389. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev* 2011;2:CD008794
390. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. *Am J Gastroenterol* 2012;107:1409-22 .
391. Moran GW, Lim AW, Bailey JL et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* 2013;38:1002-24.
392. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006;295 :2275-85

393. Moulis G, Sommet A, Bene J, *et al.* Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. *PLoSOne* 2012;7:e48991 .
394. Mariette X, Matucci-Cerinic M, Pavelka K, *et al.* Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis* 2011;70:1895-904
395. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, *et al.* Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *JAMA* 2012;308:898-908 .
396. Lichtenstein GR, RutgeertsP, Sandborn WJ, *et al.* A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. *Am J Gastroenterol* 2012; 107:1051-1063.
397. Lichtenstein GR, Feagan BG, Cohen RD, *et al.* Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. *Am J Gastroenterol* 2014;109:212–23.
398. Haynes K, Beukelman T, Curtis JR, *et al.* Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. *Arthritis Rheum* 2013;65:48-58.
399. Biancone L, Orlando A, Kohn A, *et al.* Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. *Gut*. 2006;55:228-33.

400. Biancone L, Petruzzello C, Orlando A, et al. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. *Inflamm Bowel Dis* 2011;17:758-66.
401. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. *Clin Gastroenterol Hepatol* 2008;6:644–53.
402. Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with anti-tumour necrosis factor- α therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* 2014;39:447–58.
403. Andersen NN, Pasternak B, Basit S, et al. Association between tumor necrosis factor- α antagonists and risk of cancer in patients with inflammatory bowel diseases. *JAMA* 2014;311 :2406–13.
404. Biancone L, Armuzzi A, Scribano ML, et al. Inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case-control IG-IBD study. *J Crohns Colitis* 2016 Mar 1. pii: jjw048. [Epub ahead of print],
405. van der Woude JC, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. *J Crohns Colitis* 2010;4:493–510
406. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. *Rheumatology* 2014;53:1377-85.
407. Lichtenstein G, Cohen R, Feagan B, et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry. *Gastroenterol* 2004;126(Suppl 4):A54.

408. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol* 2004;99:2385–92.
409. Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. *Inflamm Bowel Dis* 2014;20:495-501
410. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. *Reprod Toxicol* 2014;43:78-84
411. Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel disease exposed to anti-TNF α therapy during pregnancy: three-center study. *Scand J Gastroenterol* 2013;48:951-8.
412. Gisbert JP, Chaparro M. Safety of anti-TNG agents during pregnancy and breastfeeding in women with inflammatory bowel disease. *Am J Gastroenterol* 2013;108:1426-38.
413. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013;11:286-92.
414. Bröms G, Granath F, Ekbom A, et al. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy. *Clin Gastroenterol Hepatol*. 2016;14:234-41.
415. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. *Gastroenterology*. 2016 Apr 8. pii: S0016-5085(16)30054-3 [Epub ahead of print].

416. de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. *Gut*. 2015 May 12. pii: gutjnl-2015-309321. [Epub ahead of print]
417. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin Gastroenterol Hepatol* 2004;2:542–53.
418. Osterman MT, Sandborn WJ, Colombel JF, et al. *Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology* 2014; 146:941-949.
419. Navarro JT, Ribera JM, Mate JL, et al. *Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Lymphoma* 2003;44:531-3.
420. Mackey AC, Green L, Liang LC, et al. *Hepatosplenic T-cell lymphoma associated with Infliximab use in young patients treated with for inflammatory bowel disease. J Pediatr Gastroenterol Nutr* 2007;44: 265-7.
421. Shale MS, Kanfer E, Panaccione R, et al. *Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut* 2008;57:1639-41.
422. Thai A, Prindiville T. *Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis* 2010;4: 511-22.
423. Sultan K, Korelitz BI, Present D, et al. *Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis.* 2012; 18:1855-8.
424. McKenna MR, Stobaugh DJ, Deepak P. *Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor- α inhibitor monotherapy and in combination with thiopurines: analysis*

- of the Food and Drug Administration Adverse Event Reporting System. J Gastrointest Liver Dis. 2014;23:267-71.*
425. Ulrich C, Degen A, Patel MJ, et al. Sunscreens in organ transplant patients. *Nephrol Dial Transplant* 2008;23:1805-1808.
426. Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. *Expert Opin Drug Saf.* 2016;15(4):493-501.
427. Shelton E, Laharie D, Scott FI, et al. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. *Gastroenterology.* 2016;151(1):97-109.
428. Sandborn W, Feagan B, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2013 ;369:711–721.
429. Sands B, Feagan B, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology* 2014;147: 618–627.
430. Arniot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol* 2016 Feb 22. pii: S1542-3565(16)00164-6.. [Epub ahead of print]
431. Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. *J Crohn Colitis* 2016;10:402-9.
432. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut* 2016 Feb 18. pii: gutjnl-2015-311079.. [Epub ahead of print].

433. Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. *Ther Adv Gastroenterol* 2016; 9 330-338.
434. Colombel J, Sands B, Hanauer S, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. *Am J Gastroenterol* 2013;108: S502.
435. Wang M, Zhang L, Han W, et al. PRISMA - efficacy and safety of vedolizumab for inflammatory bowel diseases. *Medicine* 2104;93: e326.
436. Katz S, Pardi D. Inflammatory bowel disease of the elderly: Frequently asked questions (FAQs). *Am J Gastroenterol* 2011;106:1889–1897.
437. Sandborn W, Colombel J, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2005;353:1912–1925.

Table I. Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence*

Question	Level 1	Level 2	Level 3	Level 4	Level 5
How common is the problem?	Local and current random sample surveys (or censuses)	Systematic review of surveys that allow matching to local circumstances	Local non-random sample	Case-series	n/a
Is this diagnostic or monitoring test accurate? (Diagnosis)	Systematic review of cross sectional studies with consistently applied reference standard and blinding	Individual cross sectional studies with consistently applied reference standard and blinding	Non-consecutive studies, or studies without consistently applied reference standards	Case-control studies, or "poor or non-independent reference standard	Mechanism-based reasoning
What will happen if we do not add a therapy?	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial	Case-series or case-control studies, or	n/a

(Prognosis)				poor quality prognostic cohort study	
Does this intervention help? (Treatment Benefits)	Systematic review of randomized trials or <i>n</i> -of-1 trials	Randomized trial or observational study with dramatic effect	Non-randomized controlled cohort/follow-up study	Case-series, case-control studies, or historically controlled studies	Mechanism-based reasoning
What are the COMMON harms? (Treatment Harms)	Systematic review of randomized trials, systematic review of nested case-control studies, <i>n</i> -of-1 trial with the patient you are raising the question about, or observational study with	Individual randomized trial or (exceptionally) observational study with dramatic effect	Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm (For long-term harms the duration of follow-up must be sufficient.)	Case-series, case-control, or historically controlled studies	Mechanism-based reasoning

	dramatic effect				
What are the RARE harms? (Treatment Harms)	Systematic review of randomized trials or <i>n</i> -of-1 trial	Randomized trial or (exceptionally) observational study with dramatic effect			
Is this (early detection) test worthwhile? (Screening)	Systematic review of randomized trials	Randomized trial	Non-randomized controlled cohort/follow-up study	Case-series, case-control, or historically controlled studies	Mechanism-based reasoning

* Modified from Reference 37.

Table II - The FDA Pregnancy Category Chart *

A	Category Adequate research has been done with the conclusion that drugs in this category are not likely to cause any harm to the fetus in the first trimester as well as later in pregnancy.
B	Category Studies carried out on animals have shown no adverse effects on the fetus; however, there is a lack of controlled studies on human pregnancy.
C	Category Animal studies have shown evidence of harmful effects on the fetus; however, no controlled study has been done on a human pregnancy. The medicines may be prescribed in cases where the potential benefits outweigh the possible adverse effects.

D	Category Studies done on human pregnancy have shown positive risks to the fetus. However, doctors might prescribe them in certain cases where the potential benefits outweigh the risks.
X	Category Both human and animal studies have shown positive risks to the fetus, with the adverse effects extending to serious birth defects, miscarriage and fetal death. The possible risks of using these medicines outweigh any potential benefits.

* Modified from Reference 84.